WO2024003837A1 - Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer - Google Patents
Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer Download PDFInfo
- Publication number
- WO2024003837A1 WO2024003837A1 PCT/IB2023/056787 IB2023056787W WO2024003837A1 WO 2024003837 A1 WO2024003837 A1 WO 2024003837A1 IB 2023056787 W IB2023056787 W IB 2023056787W WO 2024003837 A1 WO2024003837 A1 WO 2024003837A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- egfr
- seq
- bispecific anti
- administered
- met antibody
- Prior art date
Links
- 208000000461 Esophageal Neoplasms Diseases 0.000 title claims abstract description 91
- 206010030155 Oesophageal carcinoma Diseases 0.000 title claims abstract description 90
- 201000004101 esophageal cancer Diseases 0.000 title claims abstract description 90
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 87
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 85
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 85
- 230000002496 gastric effect Effects 0.000 title abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 237
- 102000001301 EGF receptor Human genes 0.000 claims abstract description 160
- 108060006698 EGF receptor Proteins 0.000 claims abstract description 160
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims abstract description 8
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 127
- 238000002560 therapeutic procedure Methods 0.000 claims description 59
- 201000011510 cancer Diseases 0.000 claims description 34
- 238000002512 chemotherapy Methods 0.000 claims description 32
- 230000001225 therapeutic effect Effects 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 27
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 19
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 17
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 17
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 17
- 238000011518 platinum-based chemotherapy Methods 0.000 claims description 17
- 108091008605 VEGF receptors Proteins 0.000 claims description 16
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 16
- 238000002626 targeted therapy Methods 0.000 claims description 15
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 claims description 14
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 13
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 13
- 230000001387 anti-histamine Effects 0.000 claims description 13
- 239000000739 antihistaminic agent Substances 0.000 claims description 13
- 229960004316 cisplatin Drugs 0.000 claims description 13
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 13
- 229960002949 fluorouracil Drugs 0.000 claims description 13
- 239000003862 glucocorticoid Substances 0.000 claims description 13
- 229930012538 Paclitaxel Natural products 0.000 claims description 12
- 230000003474 anti-emetic effect Effects 0.000 claims description 12
- 230000001754 anti-pyretic effect Effects 0.000 claims description 12
- 239000002111 antiemetic agent Substances 0.000 claims description 12
- 239000002221 antipyretic Substances 0.000 claims description 12
- 229960001592 paclitaxel Drugs 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 12
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 12
- 238000011127 radiochemotherapy Methods 0.000 claims description 11
- 229960004768 irinotecan Drugs 0.000 claims description 10
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 10
- 238000001959 radiotherapy Methods 0.000 claims description 10
- 229960002633 ramucirumab Drugs 0.000 claims description 10
- 238000009169 immunotherapy Methods 0.000 claims description 9
- 229960001756 oxaliplatin Drugs 0.000 claims description 9
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 9
- 229960000575 trastuzumab Drugs 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 229960000397 bevacizumab Drugs 0.000 claims description 8
- 150000004676 glycans Chemical group 0.000 claims description 8
- 208000037819 metastatic cancer Diseases 0.000 claims description 8
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 8
- 229940127240 opiate Drugs 0.000 claims description 8
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 7
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 7
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims description 7
- 229960004117 capecitabine Drugs 0.000 claims description 7
- 229960004562 carboplatin Drugs 0.000 claims description 7
- 190000008236 carboplatin Chemical compound 0.000 claims description 7
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 7
- 229950007221 nedaplatin Drugs 0.000 claims description 7
- 190000005734 nedaplatin Chemical compound 0.000 claims description 7
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 5
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 5
- 229940116977 epidermal growth factor Drugs 0.000 claims description 5
- 229940008421 amivantamab Drugs 0.000 description 104
- 206010028980 Neoplasm Diseases 0.000 description 95
- 230000004044 response Effects 0.000 description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 61
- 201000010099 disease Diseases 0.000 description 53
- 238000003364 immunohistochemistry Methods 0.000 description 43
- 239000003814 drug Substances 0.000 description 36
- 238000012216 screening Methods 0.000 description 35
- 230000027455 binding Effects 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 33
- 229940079593 drug Drugs 0.000 description 32
- 239000000427 antigen Substances 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 230000037396 body weight Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 27
- 238000001802 infusion Methods 0.000 description 26
- 230000003442 weekly effect Effects 0.000 description 19
- 239000000090 biomarker Substances 0.000 description 17
- 230000004614 tumor growth Effects 0.000 description 17
- 238000010186 staining Methods 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000002483 medication Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 206010061818 Disease progression Diseases 0.000 description 13
- 230000005750 disease progression Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 230000005847 immunogenicity Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000001574 biopsy Methods 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 206010051792 Infusion related reaction Diseases 0.000 description 8
- 208000029523 Interstitial Lung disease Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 7
- 238000011225 antiretroviral therapy Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000009097 single-agent therapy Methods 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 5
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 238000011319 anticancer therapy Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229960004584 methylprednisolone Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 229960005343 ondansetron Drugs 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 206010059282 Metastases to central nervous system Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 229960000520 diphenhydramine Drugs 0.000 description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005734 heterodimerization reaction Methods 0.000 description 4
- 230000002998 immunogenetic effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000009121 systemic therapy Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000282577 Pan troglodytes Species 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229950005852 capmatinib Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 3
- 229940121647 egfr inhibitor Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 229960003151 mercaptamine Drugs 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 229960000620 ranitidine Drugs 0.000 description 3
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical group [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010062878 Gastrooesophageal cancer Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000032818 Microsatellite Instability Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960004993 dimenhydrinate Drugs 0.000 description 2
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 201000006974 gastroesophageal cancer Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009532 heart rate measurement Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 238000013388 immunohistochemistry analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229960005222 phenazone Drugs 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000037922 refractory disease Diseases 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 238000012502 risk assessment Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 238000009528 vital sign measurement Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229940086568 Alpha mannosidase I inhibitor Drugs 0.000 description 1
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001069765 Fridericia <angiosperm> Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- YINZYTTZHLPWBO-UHFFFAOYSA-N Kifunensine Natural products COC1C(O)C(O)C(O)C2NC(=O)C(=O)N12 YINZYTTZHLPWBO-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241001436793 Meru Species 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 206010063916 Metastatic gastric cancer Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037765 Radiation pneumonitis Diseases 0.000 description 1
- 208000036999 Reaction to drug excipients Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 238000000932 closed testing procedure Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 210000003236 esophagogastric junction Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- OIURYJWYVIAOCW-VFUOTHLCSA-N kifunensine Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2NC(=O)C(=O)N12 OIURYJWYVIAOCW-VFUOTHLCSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960002131 palonosetron Drugs 0.000 description 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229940120723 recombinant human hyaluronidase Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- FIVSJYGQAIEMOC-ZGNKEGEESA-N rolapitant Chemical compound C([C@@](NC1)(CO[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2C=CC=CC=2)C[C@@]21CCC(=O)N2 FIVSJYGQAIEMOC-ZGNKEGEESA-N 0.000 description 1
- 229960001068 rolapitant Drugs 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Definitions
- sequence listing of the present application is submitted electronically via The United States Patent and Trademark Center Patent Center as an XML formatted sequence listing with a file name “JBI6733WOPCTlSEQLIST.xml”, creation date of June 28, 2023, and a size of 20 kilobytes (KB).
- This sequence listing submitted is part of the specification and is herein incorporated by reference in its entirety.
- the present disclosure relates to methods of treating gastric or esophageal cancer with a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c- Met) antibody.
- EGFR bispecific anti-epidermal growth factor receptor
- c- Met hepatocyte growth factor receptor
- GC Gastric cancer
- HER2 human epidermal growth factor receptor 2
- PD-L1 programmed deathligand 1
- the first line treatment generally includes fluoropyrimidine plus cisplatin or oxaliplatin plus trastuzumab (depending on HER2 status).
- the observed overall response rate for the guideline-recommended initial treatment varies widely (e.g., between 35% to 68% for the combination therapy with oral fluoropyrimidine (S-l) in Japan (Bang 2010; Kurokawa 2014)). Available treatment options after first line treatment are limited.
- NCCN recommendations are chemotherapy as a single agent, ramucirumab plus paclitaxel, immune checkpoint inhibitor, or fluorouracil plus irinotecan.
- the overall response rate for the second and third line treatments is limited and the median progression-free survival is very low.
- Esophageal cancer is the eighth most common cancer worldwide and ranked sixth among all cancers in mortality in 2018. Similar to GC, EC is highly prevalent in Asian countries accounting for over 75% of new cases in 2018. Squamous cell carcinoma and adenocarcinoma are two major histologies of primary ECs. However, predominant EC histology varies between geographical regions. The predominant histology observed among the Caucasian population is adenocarcinoma whereas squamous histology predominates Asian countries. Treatment commonly includes surgery, radiation therapy, chemoradiation therapy, and chemotherapy. The NCCN guideline recommendations for the first line therapies are identical to GC regimens due to the nature of histological similarities (NCCN Guidelines 2020).
- kits for treating gastric or esophageal cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.
- EGFR bispecific anti-epidermal growth factor receptor
- c-Met hepatocyte growth factor receptor
- the present disclosure provides a method of treating gastric cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
- the first domain that specifically binds EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
- the bispecific anti- EGFR/c-Met antibody is an IgGl isotype.
- the bispecific anti- EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
- the bispecific anti- EGFR/c-Met antibody comprises a biantennary glycan structure with a fucose content of about between 1% to about 15%.
- the bispecific anti- EGFR/c-Met antibody is administered intravenously or subcutaneously to the subject.
- the bispecific anti- EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 3400 mg.
- the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 350 mg, 700 mg, about 750 mg, about 800 mg, about 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, 2000 mg, 2100 mg, 2200 mg, 2240 mg, 2300 mg, 2400 mg, 2500 mg, 2600 mg, 2700 mg, 2800 mg, 2900 mg, 3000 mg, 3100 mg, 3200 mg, 3300 mg, 3360 mg, or 3400 mg.
- the bispecific anti- EGFR/c-Met antibody is administered at a dose of 1050 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1600 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1750 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg.
- the bispecific anti- EGFR/c-Met antibody is administered subcutaneously or intradermally to the subject. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally at a dose sufficient to achieve a therapeutic effect in the subject.
- the bispecific anti- EGFR/c-Met antibody is administered intravenously to the subject. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered intravenously at a dose sufficient to achieve a therapeutic effect in the subject.
- the bispecific anti- EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter. In some embodiments, the first dose of the bispecific anti-EGFR/c-Met antibody is administered over two days.
- one or more cells of the gastric cancer express EGFR and/or cMet.
- the subject has received a prior treatment.
- the prior treatment comprises a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a combination thereof.
- the chemotherapy comprises a fluoropyrimidine- based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof.
- the fluoropyrimidine is 5 -fluorouracil or capecitabine.
- the platinum-based chemotherapy is cisplatin, oxaliplatin, carboplatin, or nedaplatin.
- the targeted therapy comprises an anti-HER2 therapy or anti- VEGF/VEGFR therapy.
- the anti-HER2 therapy comprises trastuzumab.
- the anti-VEGF/VEGFR therapy comprises bevacizumab or ramucirumab.
- the method further comprises administering at least one additional therapeutic to the subject.
- the additional therapeutic comprises a glucocorticosteroid, antihistamine, antipyretic, H2- antagonist, antiemetic, opiate, or any combination thereof.
- the gastric cancer is an advanced or metastatic cancer.
- the subject is human.
- the present disclosure provides a method of treating esophageal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
- the bispecific anti- EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6, and wherein the second domain that binds c-Met comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
- HCDR1 heavy chain complementarity determining region 1
- the first domain that specifically binds EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
- the bispecific anti- EGFR/c-Met antibody is an IgGl isotype.
- the bispecific anti- EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
- the bispecific anti- EGFR/c-Met antibody comprises a biantennary glycan structure with a fucose content of about between 1% to about 15%.
- the bispecific anti- EGFR/c-Met antibody is administered intravenously or subcutaneously to the subject.
- the bispecific anti- EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 3400 mg.
- the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 350 mg, 700 mg, about 750 mg, about 800 mg, about 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, 2000 mg, 2100 mg, 2200 mg, 2240 mg, 2300 mg, 2400 mg, 2500 mg, 2600 mg, 2700 mg, 2800 mg, 2900 mg, 3000 mg, 3100 mg, 3200 mg, 3300 mg, 3360 mg, or 3400 mg.
- the bispecific anti- EGFR/c-Met antibody is administered at a dose of 1050 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1600 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1750 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg.
- the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg. [0035] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody is administered subcutaneously or intradermally to the subject. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally at a dose sufficient to achieve a therapeutic effect in the subject.
- the bispecific anti- EGFR/c-Met antibody is administered intravenously to the subject. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered intravenously at a dose sufficient to achieve a therapeutic effect in the subject.
- the bispecific anti- EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter. In some embodiments, the first dose of the bispecific anti-EGFR/c-Met antibody is administered over two days.
- one or more cells of the esophageal cancer express EGFR and/or cMet.
- the subject has received a prior treatment.
- the prior treatment comprises a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a combination thereof.
- the chemotherapy comprises a fluoropyrimidine- based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof.
- the fluoropyrimidine is 5 -fluorouracil or capecitabine.
- the platinum-based chemotherapy is cisplatin, oxaliplatin, carboplatin, or nedaplatin.
- the targeted therapy comprises an anti-HER2 therapy or anti- VEGF/VEGFR therapy.
- the anti-HER2 therapy comprises trastuzumab.
- the anti-VEGF/VEGFR therapy comprises bevacizumab or ramucirumab.
- the method further comprises administering at least one additional therapeutic to the subject.
- the additional therapeutic is a glucocorticosteroid, antihistamine, antipyretic, H2-antagonist, antiemetic, opiate, or any combination thereof.
- the esophageal cancer is an advanced or metastatic cancer.
- the subject is human.
- Figure 1 depicts one aspect of the Phase 2 study described in Example 1.
- Figures 2A-2L show tumor growth curves (expressed as Mean ⁇ SEM) over time in a series of esophageal patient-derived xenografts (PDX) models.
- Figures 3A-3F show tumor growth curves (expressed as Mean ⁇ SEM) over time in a series of gastric PDX models.
- Figure 4 shows relative EGFR and c-Met H-scores together with anti-tumor activity of amivantamab in a series of esophageal PDX models.
- Figure 5 shows relative EGFR and c-Met H-scores together with anti-tumor activity of amivantamab in a series of gastric PDX models.
- Figure 6 shows the overall response for gastric cancer patients in response evaluable population.
- Figure 7 shows the overall response for gastric cancer patients in all treated population.
- Figure 8 shows the overall response for esophageal cancer patients in response evaluable population.
- Figure 9 shows the overall response for esophageal cancer patients in all treated population.
- Figure 10 shows the overall response for esophageal cancer in patients treated with 1750 mg amivantamab in response evaluable population.
- RTK Receptor tyrosine kinases
- Epidermal growth factor receptor an RTK in the HER family, is normally expressed in tissues of epithelial, mesenchymal, and neuronal origin. Binding of any of its 7 ligands, including EGF, induces diverse cellular responses, including differentiation, proliferation, migration, and survival (Olayioye 2000).
- the mesenchymal-epithelial transition factor (cMet or MET) receptor is also an RTK, expressed in normal epithelial cells (Prat 1991), with a role in growth and homeostasis, including embryonic development, angiogenesis, and wound healing (Sattler 2011). cMet is activated by a single specific ligand, hepatocyte growth factor, also known as scatter factor.
- EGFR or cMet has been implicated as a poor prognostic factor in GC (Aydin 2014; Gao 2013; Galizia 2007; Atmaca 2012; Fuse 2016) and EC (Wang 2007; Brand 2011; Ozawa 2015).
- EGFR tyrosine kinase inhibitors include anti-EGFR antibodies and EGFR tyrosine kinase inhibitors (TKIs)
- TKIs EGFR tyrosine kinase inhibitors
- Previous studies have failed to show efficacy of cetuximab and panitumumab, anti-EGFR antibodies, for the treatment of GC or gefitinib, EGFR tyrosine kinase inhibitor, in EC in non-biomarker selected population (Lordick 2013; Waddell 2013; Dutton 2014).
- the present disclosure provides methods and compositions useful for treating gastric or esophageal cancer by targeting both EGFR and cMet. Definitions
- “Co-administration,” “administration with,” “administration in combination with,” “in combination with” or the like, encompass administration of the selected therapeutics or drugs to a single patient, and are intended to include treatment regimens in which the therapeutics or drugs are administered by the same or different route of administration or at the same or different time.
- Treat”, “treating” or “treatment” of a disease or disorder such as cancer refers to accomplishing one or more of the following: reducing the severity and/or duration of the disorder, inhibiting worsening of symptoms characteristic of the disorder being treated, limiting or preventing recurrence of the disorder in subjects that have previously had the disorder, or limiting or preventing recurrence of symptoms in subjects that were previously symptomatic for the disorder.
- Prevent means preventing that a disorder occurs in subject.
- “Responsive”, “responsiveness” or “likely to respond” refers to any kind of improvement or positive response, such as alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
- “Therapeutically effective amount” refers to an amount effective, at doses and for periods of time necessary, to achieve a desired therapeutic result.
- a therapeutically effective amount may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic or combination of therapeutics that include, for example, improved well-being of the patient, decrease or shrinkage of the size of a tumor, arrested or slowed growth of a tumor, and/or absence of metastasis of cancer cells to other locations in the body.
- “Refractory” refers to a disease that does not respond to a treatment. A refractory disease can be resistant to a treatment before or at the beginning of the treatment, or a refractory disease can become resistant during a treatment.
- Relapsed refers to the return of a disease or the signs and symptoms of a disease after a period of improvement after prior treatment with a therapeutic.
- Subject includes any human or nonhuman animal.
- Nonhuman animal includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc.
- the terms “subject” and “patient” are used interchangeably herein.
- “About” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. Unless explicitly stated otherwise within the Examples or elsewhere in the Specification in the context of a particular assay, result or embodiment, “about” means within one standard deviation per the practice in the art, or a range of up to 5%, whichever is larger.
- Cancer refers to an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize (spread) to other areas of a patient’s body.
- EGFR or c-Met or MET expressing cancer refers to cancer that has detectable expression of EGFR or c-Met or has EGFR or c-Met mutation or amplification.
- EGFR or c-Met expression, amplification and mutation status can be detected using know methods, such as sequencing, fluorescent in situ hybridization, immunohistochemistry, flow cytometry or western blotting.
- Epidermal growth factor receptor or “EGFR” refers to the human EGFR (also known as HER1 or ErbBl (Ullrich et al., Nature 309:418-425, 1984)) having the amino acid sequence shown in GenBank accession number NP_005219, as well as naturally occurring variants thereof.
- Hepatocyte growth factor receptor or “c-Met” or “MET” as used herein refers to the human c-Met having the amino acid sequence shown in GenBank Accession No: NP_001120972 and natural variants thereof.
- Bispecific anti-EGFR/c-Met antibody or “bispecific EGFR/c-Met antibody” refers to a bispecific antibody having a first domain that specifically binds EGFR and a second domain that specifically binds c-Met.
- the domains specifically binding EGFR and c-Met are typically VH/VL pairs, and the bispecific anti-EGFR/c-Met antibody is monovalent in terms of binding to EGFR and c-Met.
- “Specific binding” or “specifically binds” or “specifically binding” or “binds” refer to an antibody binding to an antigen or an epitope within the antigen with greater affinity than for other antigens.
- the antibody binds to the antigen or the epitope within the antigen with an equilibrium dissociation constant (KD) of about 5xl0 -8 M or less, for example about IxlO -9 M or less, about IxlO 10 M or less, about IxlO 11 M or less, or about IxlO 12 M or less, typically with the KD that is at least one hundred-fold less than its KD for binding to a nonspecific antigen (e.g., BSA, casein).
- KD equilibrium dissociation constant
- the dissociation constant may be measured using known protocols.
- Antibodies that bind to the antigen or the epitope within the antigen may, however, have cross-reactivity to other related antigens, for example to the same antigen from other species (homologs), such as human or monkey, for example Macaca fascicularis (cynomolgus, cyno) or Pan troglodytes (chimpanzee, chimp). While a monospecific antibody binds one antigen or one epitope, a bispecific antibody binds two distinct antigens or two distinct epitopes.
- Antibodies is meant in a broad sense and includes immunoglobulin molecules including monoclonal antibodies including murine, human, humanized and chimeric monoclonal antibodies, antigen binding fragments, multispecific antibodies, such as bispecific, trispecific, tetraspecific etc., dimeric, tetrameric or multimeric antibodies, single chain antibodies, domain antibodies and any other modified configuration of the immunoglobulin molecule that comprises an antigen binding site of the required specificity.
- “Full length antibodies” are comprised of two heavy chains (HC) and two light chains (LC) inter-connected by disulfide bonds as well as multimers thereof (e.g., IgM).
- Each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (comprised of domains CHI, hinge, CH2 and CH3).
- Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL).
- the VH and the VL regions may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with framework regions (FR).
- CDR complementarity determining regions
- FR framework regions
- Each VH and VL is composed of three CDRs and four FR segments, arranged from amino-to-carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
- CDR complementarity determining regions
- CDR CDR
- HCDR1 CDR1
- HCDR2 CDR3
- LCDR1 CDR2
- LCDR3 CDR3
- Immunoglobulins may be assigned to five major classes, IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence.
- IgA and IgG are further sub-classified as the isotypes IgAl, IgA2, IgGl, IgG2, IgG3 and IgG4.
- Antibody light chains of any vertebrate species may be assigned to one of two clearly distinct types, namely kappa (K) and lambda (X), based on the amino acid sequences of their constant domains.
- Antigen binding fragment refers to a portion of an immunoglobulin molecule that binds an antigen.
- Antigen binding fragments may be synthetic, enzymatically obtainable or genetically engineered polypeptides and include the VH, the VL, the VH and the VL, Fab, F(ab')2, Fd and Fv fragments, domain antibodies (dAb) consisting of one VH domain or one VL domain, shark variable IgNAR domains, camelized VH domains, minimal recognition units consisting of the amino acid residues that mimic the CDRs of an antibody, such as FR3-CDR3- FR4 portions, the HCDR1, the HCDR2 and/or the HCDR3 and the LCDR1, the LCDR2 and/or the LCDR3.
- VH and VL domains may be linked together via a synthetic linker to form various types of single chain antibody designs where the VH/VL domains may pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate single chain antibody constructs, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody; described for example in Int. Patent Publ. Nos. W01998/44001, WO1988/01649, WO1994/13804 and W01992/01047.
- scFv single chain Fv
- “Monoclonal antibody” refers to an antibody obtained from a substantially homogenous population of antibody molecules, i.e., the individual antibodies comprising the population are identical except for possible well-known alterations such as removal of C- terminal lysine from the antibody heavy chain or post-translational modifications such as amino acid isomerization or deamidation, methionine oxidation or asparagine or glutamine deamidation.
- Monoclonal antibodies typically bind one antigenic epitope.
- a bispecific monoclonal antibody binds two distinct antigenic epitopes.
- Monoclonal antibodies may have heterogeneous glycosylation within the antibody population.
- Monoclonal antibody may be monospecific or multispecific such as bispecific, monovalent, bivalent or multivalent.
- Recombinant refers to DNA, antibodies and other proteins that are prepared, expressed, created or isolated by recombinant means when segments from different sources are joined to produce recombinant DNA, antibodies or proteins.
- Bispecific refers to an antibody that specifically binds two distinct antigens or two distinct epitopes within the same antigen.
- the bispecific antibody may have cross-reactivity to other related antigens, for example to the same antigen from other species (homologs), such as human or monkey, for example Macaca cynomolgus (cynomolgus, cyno) or Pan troglodytes, or may bind an epitope that is shared between two or more distinct antigens.
- Antagonist refers to a molecule that, when bound to a cellular protein, suppresses at least one reaction or activity that is induced by a natural ligand of the protein.
- a molecule is an antagonist when the at least one reaction or activity is suppressed by at least about 20%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% more than the at least one reaction or activity suppressed in the absence of the antagonist (e.g., negative control), or when the suppression is statistically significant when compared to the suppression in the absence of the antagonist.
- PD-(L)1 axis inhibitor refers to a molecule that inhibits PD-1 downstream signaling.
- PD-(L)1 axis inhibitor may be a molecule that binds PD-1, PD-L1 or PD-L2.
- Low fucose or “low fucose content” as used in the application refers to antibodies with fucose content of about between 1 %- 15 %.
- Normal fucose or “normal fucose content” as used herein refers to antibodies with fucose content of about over 50%, typically about over 80% or over 85%.
- One aspect of the disclosure provides a method of treating gastric or esophageal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
- the disclosure provides a method of treating gastric cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
- Gastric cancer referred to herein also includes esophagogastric junction (GEJ) cancer.
- the gastric cancer is adenocarcinoma.
- the gastric cancer is an advanced or metastatic cancer.
- the gastric cancer may have metastasized to the esophagus, the small intestine, lymph nodes, organs, bones, or combinations thereof.
- the disclosure provides a method of treating esophageal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
- the esophageal cancer is adenocarcinoma. In some embodiments, the esophageal cancer is squamous cell carcinoma. In some embodiments, the esophageal cancer is an advanced or metastatic cancer. For example, the esophageal cancer may have metastasized to the lung, the small intestine, lymph nodes, organs, bones, or combinations thereof.
- the subject has received prior treatment.
- the prior treatment may include a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a combination thereof.
- the chemotherapy is a fluoropyrimidine-based chemotherapy, such as 5 -fluorouracil or capecitabine.
- the chemotherapy is a platinum-based chemotherapy.
- platinum-based chemotherapies include, but not limited to, cisplatin, oxaliplatin, carboplatin, or nedaplatin.
- Additional examples of chemotherapy may include taxanes (e.g., paclitaxel, docetaxel), topoisomerase inhibitors (e.g., irinotecan, camptothecin), or a combination thereof.
- the targeted therapy is an anti-HER2 therapy or anti- VEGF/VEGFR therapy.
- anti-HER2 therapy include trastuzumab.
- anti-VEGF/VEGFR therapy include bevacizumab or ramucirumab.
- the prior treatment comprises an immunotherapy such as checkpoint inhibitors.
- the immunotherapy comprises a PD-(L)1 axis inhibitor, or a CTLA-4 inhibitor.
- PD-(L) 1 axis inhibitors include atezolizumab, nivolumab, pembrolizumab, camrelizumab, and tislelizumab.
- CTLA-4 inhibitors include ipilimumab.
- the prior treatment comprises an anti-VEGF/VEGFR therapy.
- anti-VEGF/VEGFR therapy include bevacizumab and ramucirumab.
- the prior treatment comprises fluoropyrimidine and cisplatin. [00104] In some embodiments, the prior treatment comprises oxaliplatin and trastuzumab. [00105] In some embodiments, the prior treatment comprises ramucirumab and paclitaxel. [00106] In some embodiments, the prior treatment comprises fluorouracil and irinotecan.
- the prior treatment comprises fluorouracil and cisplatin.
- the subject is treatment naive.
- one or more cells of the gastric or esophageal cancer express EGFR and/or cMet.
- EGFR or c-Met expression can be detected using know methods, such as fluorescent in situ hybridization, immunohistochemistry (IHC), flow cytometry or western blotting.
- expression of EGFR and/or cMet is detected using immunohistochemistry (IHC), which measures EGFR and/or cMet protein levels on the cell surface.
- IHC immunohistochemistry
- a membrane staining intensity score (0, 1+, 2+, or 3+) may be determined for each cell in a fixed field.
- the tumor sample can be fixed in formalin paraffin embedded tissue (FFPE).
- the subject who receives the bispecific anti-EGFR/c-Met antibody has a staining intensity score of 1+ or above based on EGFR and/or cMet expression in a tumor sample obtained from the subject as determined by an IHC assay.
- the subject who receives the bispecific anti-EGFR/c-Met antibody has a staining intensity score of 2+ or above based on EGFR and/or cMet expression in a tumor sample obtained from the subject as determined by an IHC assay.
- the subject who receives the bispecific anti-EGFR/c-Met antibody has a staining intensity score of 3+ based on EGFR and/or cMet expression in a tumor sample obtained from the subject as determined by an IHC assay.
- an H score (or histo score) may be assigned to a tumor sample as a semiquantitative approach useful for analyses of immunohistochemical results (Hirsch FR et al., J Clin Oncol 21:3798-3807, 2003; John T et al., Oncogene 28:S14-S23, 2009, incorporated herein by reference in their entireties).
- the H score may be based on a predominant staining intensity.
- the H score may include the sum of individual H scores for each intensity level seen.
- the percentage of cells at each staining intensity level may be calculated, and finally, an H score may be assigned using the following exemplary formula: [1 x (% cells 1+) + 2 x (% cells 2+) + 3 x (% cells 3+)].
- the final calculated H score ranging from 0 to 300, may give more relative weight to higher-intensity membrane staining in a given tumor sample.
- the tumor sample may be considered either positive or a negative on the basis of a specific discriminatory threshold.
- a “combined H score” can be generated by adding an H score calculated from the analysis of one biomarker (e.g., EGFR expression) to an H score calculated from the analysis of a second biomarker (e.g., MET expression). Accordingly, the combined H score can have a range of 0 to 600.
- one biomarker e.g., EGFR expression
- a second biomarker e.g., MET expression
- the bispecific anti-EGFR/c-Met antibody may be administered in a pharmaceutically acceptable carrier.
- Carrier refers to a diluent, adjuvant, excipient, or vehicle with which the antibody of the invention is administered.
- vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- 0.4% saline and 0.3% glycine may be used to formulate the bispecific anti-EGFR/c-Met antibody.
- These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well-known sterilization techniques (e.g., filtration).
- the carrier may comprise sterile water and other excipients may be added to increase solubility or preservation. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.
- a recombinant human hyaluronidase such as rHuPH20 (CAS Registry No. 757971-58-7)
- Suitable vehicles and formulations, inclusive of other human proteins, e.g., human serum albumin are described, for example, in e.g., Remington: The Science and Practice of Pharmacy, 21st Edition, Troy, D.B. ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing pp 691-1092, See especially pp. 958-989.
- the mode of administration may be any suitable route that delivers the bispecific anti- EGFR-c-Met antibody to the host, such as parenteral administration, e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, intravaginal, rectal), using a formulation in a tablet, capsule, solution, powder, gel, particle; and contained in a syringe, an implanted device, osmotic pump, cartridge, micropump; or other means appreciated by the skilled artisan, as well known in the art.
- parenteral administration e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, intravaginal, rectal), using a formulation in a tablet, capsule, solution, powder, gel, particle; and contained in a syringe, an implanted device, osmotic pump,
- Site specific administration may be achieved by for example intratumoral, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intracardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravascular, intravesical, intralesional, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery.
- the bispecific anti-EGFR/c-Met antibody is administered intravenously.
- Exemplary intravenous formulations are disclosed in United States Patent Application Pub. No. US 2022/0064307 Al.
- the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally to the subject.
- the bispecific anti-EGFR/c-Met antibody may be administered subcutaneously or intradermally at a dose sufficient to achieve a therapeutic effect in the subject.
- Exemplary subcutaneous formulations are disclosed in United States Patent Application Pub. No. US 2022/0395573 Al.
- the bispecific anti-EGFR/c-Met antibody is administered at a dose of between about 140 mg to about 1750 mg. In some embodiments, the bispecific anti- EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 2240 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 1750 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 3340 mg.
- the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg,
- the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 350 mg, about 700 mg, about 1050 mg, about 1400 mg, about 1575 mg, about 1600 mg, about 1750 mg, about 2100 mg, about 2240 mg, about 2400 mg, or about 3360 mg,. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 350 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 700 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 750 mg.
- the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 800 mg. In some embodiments, the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 850 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 900 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 950 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1000 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1050 mg.
- the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1100 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1150 mg. In some embodiments, the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 1200 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1250 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1300 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1350 mg.
- the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1575 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1600 mg. In some embodiments, the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 1750 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 2100 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 2240 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 2400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 3360 mg.
- the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 1050 mg if the subject has a body weight of less than 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 1050 mg even if the subject has a body weight of greater than or equal to 80 kg.
- the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg if the subject has a body weight of greater than or equal to 80 kg.
- the bispecific anti-EGFR/c-Met antibody is administered once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1050 mg once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1400 mg once a week. In some embodiments, the bispecific anti-EGFR/c- Met antibody is administered about 1600 mg once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1750 mg once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 2100 mg once a week.
- the bispecific anti-EGFR/c-Met antibody is administered once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1050 mg once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1400 mg once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1600 mg once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1750 mg once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 2100 mg once in two weeks.
- the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 1575 mg if the subject has a body weight of less than 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg if the subject has a body weight of greater than or equal to 80 kg.
- the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 1600 mg if the subject has a body weight of less than 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg if the subject has a body weight of greater than or equal to 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered weekly for the first 4 weeks, and once every 2 weeks thereafter.
- the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 2400 mg if the subject has a body weight of less than 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg if the subject has a body weight of greater than or equal to 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered weekly for the first 3 weeks, and once every 3 weeks thereafter.
- the bispecific anti-EGFR/c-Met antibody is administered twice a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once in three weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once in four weeks.
- the bispecific anti-EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks.
- the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter.
- the first dose of the bispecific anti-EGFR/c-Met antibody is administered in two days.
- the first dose of the bispecific anti- EGFR/c-Met antibody may be split to two days with Day 1 (350 mg) and Day 2 (700 mg if body weight is ⁇ 80 kg or 1,050 mg if body weight is >80 kg).
- the method further comprises administering at least one additional therapeutic to the subject.
- the additional therapeutic is a glucocorticosteroid, antihistamine, antipyretic, H2-antagonist, antiemetic, opiate, or any combination thereof.
- the at least one additional therapeutic is administered prior to the one or more treatment doses.
- the glucocorticosteroid is dexamethasone, beclomethasone, betamethasone, budesonide, cortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone.
- the glucocorticosteroid is dexamethasone or methylprednisolone.
- the glucocorticosteroid is dexamethasone (10 mg) or methylprednisolone (40 mg).
- the glucocorticosteroid e.g., dexamethasone, methylprednisolone
- IV intravenously
- the glucocorticosteroid e.g., dexamethasone, methylprednisolone
- the antihistamine is diphenhydramine, brompheniramine, chlorpheniramine, clemastine, cyproheptadine, dexchlorpheniramine dimenhydrinate, doxylamine, hydroxyzine, phenindamine, azelastine, loratadine, cetirizine, desloratadine, or fexofenadine.
- the antihistamine is diphenhydramine.
- the antihistamine may be diphenhydramine (about 25-50 mg) or equivalent.
- the antihistamine medication is administered orally approximately 30-60 prior to administration of the bispecific anti-EGFR/c-Met antibody. In some embodiments, the antihistamine medication is administered intravenously approximately 15 to 30 minutes prior to administration of the bispecific anti-EGFR/c-Met antibody.
- the antipyretic is acetaminophen, ibuprofen, naproxen, ketoprofen, and nimesulide, aspirin, choline salicylate, magnesium salicylate, sodium salicylate, or phenazone (antipyrine).
- the antipyretic is acetaminophen.
- the antipyretic may be acetaminophen (about 650 mg to 1 ,000 mg) or equivalent.
- the antipyretic medication is administered intravenously approximately 15 to 30 min or orally approximately 30-60 min prior to administration of the bispecific anti-EGFR/c-Met antibody.
- the ⁇ -antagonist is ranitidine, cimetidine, famotidine, or nizatidine.
- the ⁇ -antagonist is ranitidine.
- the ⁇ -antagonist may be ranitidine (about 50 mg) or equivalent.
- the H2-antagonist medication is administered intravenously approximately 15-30 minutes prior to administration of the bispecific anti-EGFR/c-Met antibody or orally approximately 60 minutes prior to administration of the bispecific anti-EGFR/c-Met antibody.
- the antiemetic is ondansetron, meclizine, dimenhydrinate, prochlorperazine, promethazine, vitamin B6, droperidol, granisetron, metoclopramide, aprepitant, dolasetron, palonosetron, rolapitant.
- the antiemetic is ondansetron.
- the antiemetic may be ondansetron (about 16 mg) or equivalent.
- the antiemetic medication is administered intravenously approximately 15 to 30 minutes prior to administration of the bispecific anti-EGFR/c-Met antibody or orally about 15 to 30 minutes prior to administration of the bispecific anti-EGFR/c- Met antibody.
- the at least one additional therapeutic described herein is administered after the one or more treatment doses.
- the at least one additional therapeutic may be administered up to 48 hours after the one or more treatment doses if clinically indicated.
- a glucocorticosteroid e.g., dexamethasone (10 mg)
- an antihistamine e.g., diphenhydramine (25-50 mg)
- an antipyretic e.g., acetaminophen (650- 1,000 mg)
- an opiate e.g., meperidine (25-100 mg)
- an antiemetic medication may be administered intravenously (e.g., ondansetron (8-16 mg)) or orally (e.g., ondansetron (8 mg)) to the subject after the one or more treatment
- An exemplary bispecific anti-EGFR/c-Met antibody that can be used in the methods of the disclosures is amivantamab.
- Amivantamab is an IgGl anti-EGFR/c-Met bispecific antibody described in U.S. Pat. No. 9,593,164, which is incorporated herein by reference in its entirety.
- Amivantamab is a low fucose, fully human immunoglobulin G1 (IgGl)-based bispecific antibody directed against the EGFR and MET receptors, shows preclinical activity against tumors with overexpressed wild type EGFR and activation of the MET pathway.
- amivantamab targets the extracellular domain of both EGFR and MET.
- Amivantamab may have at least 3 potential mechanisms of action, including 1) inhibition of ligand-dependent signaling, 2) downregulation of EGFR and MET expression levels, and 3) initiation of antibody-dependent cellular cytotoxicity (ADCC).
- ADCC antibody-dependent cellular cytotoxicity
- Amivantamab is produced with low levels of fucosylation, which translates to an enhanced level of ADCC activity.
- the human Fcyllla receptor critical for ADCC, binds low fucose antibodies more tightly and consequently mediates more potent and effective ADCC killing of target cancer cells (Satoh, 2006).
- amivantamab can inhibit receptors that display primary resistance to EGFR TKIs (Exon 20 insertion) or have acquired either EGFR resistance mutations (T790M or C797S) or secondary activation of the MET pathway (MET amplification).
- Amivantamab is characterized by following amino acid sequences: EGFR binding arm
- the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6; and the second domain comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
- HCDR1 heavy chain complementarity determining region 1
- LCDR2 of SEQ ID NO: 2 a HCDR3 of SEQ
- the first domain that specifically binds EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14; and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
- the bispecific anti-EGFR/c-Met antibody is an IgGl isotype.
- the bispecific anti-EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
- the bispecific anti-EGFR/c-Met antibody comprises one or more Fc silencing mutations.
- the one or more Fc silencing mutations decrease affinity to Fey receptors.
- the one or more Fc silencing mutations comprise V234A/G237A/P238S/H268A/V309L/A330S/P331S.
- the bispecific anti-EGFR/c-Met antibody comprises a biantennary glycan structure with a fucose content between about 1% to about 15%.
- Antibodies with reduced fucose content can be made using different methods reported to lead to the successful expression of relatively high defucosylated antibodies bearing the biantennary complex-type of Fc oligosaccharides such as control of culture osmolality (Konno et al., Cytotechnology 64(: 249-65, 2012), application of a variant CHO line Lecl3 as the host cell line (Shields et al., J Biol Chem 277:26733-26740, 2002), application of a variant CHO line EB66 as the host cell line (Olivier et al., MAbs ;2(4), 2010; Epub ahead of print; PMID:20562582), application of a rat hybridoma cell line YB2/0 as the host cell line (Shinkawa
- bispecific anti-EGFR/c-Met antibodies may also be used in the methods of the disclosure as long as they demonstrate similar characteristics when compared to amivantamab as described in U.S. Pat. No. 9,593,164.
- Bispecific anti-EGFR/c-Met antibodies that may be used in the methods of the disclosure may also be generated by combining EGFR binding VH/VL domains and c-Met binding VH/VL domains and testing the resulting bispecific antibodies for their characteristics as described in U.S. Pat. No. 9,593,164.
- Bispecific anti-EGFR/c-Met antibodies used in the methods of the disclosure may be generated for example using Fab arm exchange (or half molecule exchange) between two monospecific bivalent antibodies by introducing substitutions at the heavy chain CH3 interface in each half molecule to favor heterodimer formation of two antibody half molecules having distinct specificity either in vitro in cell-free environment or using co-expression.
- the Fab arm exchange reaction is the result of a disulfide -bond isomerization reaction and dissociationassociation of CH3 domains. The heavy chain disulfide bonds in the hinge regions of the parental monospecific antibodies are reduced.
- the resulting free cysteines of one of the parental monospecific antibodies form an inter heavy-chain disulfide bond with cysteine residues of a second parental monospecific antibody molecule and simultaneously CH3 domains of the parental antibodies release and reform by dissociation-association.
- the CH3 domains of the Fab arms may be engineered to favor heterodimerization over homodimerization.
- the resulting product is a bispecific antibody having two Fab arms or half molecules which each bind a distinct epitope, i.e. an epitope on EGFR and an epitope on c-Met.
- the bispecific antibodies of the invention may be generated using the technology described in Int.Pat. Publ. No. WO2011/131746.
- Mutations F405L in one heavy chain and K409R in the other heavy chain may be used in case of IgGl antibodies.
- IgG2 antibodies a wild-type IgG2 and a IgG2 antibody with F405L and R409K substitutions may be used.
- IgG4 antibodies a wild-type IgG4 and a IgG4 antibody with F405L and R409K substitutions may be used.
- first monospecific bivalent antibody and the second monospecific bivalent antibody are engineered to have the aforementioned mutation in the Fc region, the antibodies are incubated together under reducing conditions sufficient to allow the cysteines in the hinge region to undergo disulfide bond isomerization; thereby generating the bispecific antibody by Fab arm exchange.
- the incubation conditions may optimally be restored to non-reducing.
- Exemplary reducing agents that may be used are 2- mercaptoethylamine (2-MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2-carboxyethyl)phosphine (TCEP), L-cysteine and betamercaptoethanol.
- incubation for at least 90 min at a temperature of at least 20°C in the presence of at least 25 mM 2-MEA or in the presence of at least 0.5 mM dithiothreitol at a pH of from 5-8, for example at pH of 7.0 or at pH of 7.4 may be used.
- Bispecific anti-EGFR/c-Met antibodies used in the methods of the disclosure may also be generated using designs such as the knob-in-hole or knobs-into-holes (Genentech), CrossMAbs (Roche) and the electrostatically-matched (Chugai, Amgen, NovoNordisk, Oncomed), the LUZ-Y (Genentech), the Strand Exchange Engineered Domain body (SEEDbody)(EMD Serono), and the Biclonic (Merus).
- designs such as the knob-in-hole or knobs-into-holes (Genentech), CrossMAbs (Roche) and the electrostatically-matched (Chugai, Amgen, NovoNordisk, Oncomed), the LUZ-Y (Genentech), the Strand Exchange Engineered Domain body (SEEDbody)(EMD Serono), and the Biclonic (Merus).
- Exemplary CH3 substitution pairs forming a knob and a hole are (expressed as modified position in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): T366Y/F405A, T366W/F405W, F405W/Y407A, T394W/Y407T, T394S/Y407A, T366W/T394S, F405W/T394S and T366W/T366S_E368A_Y407V.
- CrossMAb technology in addition to utilizing the “knob-in-hole” strategy to promoter Fab arm exchange utilizes CH1/CE domain swaps in one half arm to ensure correct light chain pairing of the resulting bispecific antibody (see e.g., U.S. Patent No. 8,242,247).
- heterodimerization may be promoted by following substitutions (expressed as modified positions in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): L351 Y_F405A_Y407V/T394W, T366I_K392M_T394W/F405A_Y407V, T366L_K392M_T394W/F405A_Y407V, L351 Y_Y407A/T366A_K409F, L351Y_Y407A/T366V_K409F, Y407A/T366A_K409F, or
- SEEDbody technology may be utilized to generate bispecific antibodies of the invention.
- SEEDbodies have, in their constant domains, select IgG residues substituted with IgA residues to promote heterodimerization as described in U.S. Patent No. US20070287170.
- Mutations are typically made at the DNA level to a molecule such as the constant domain of the antibody using standard methods.
- a method of treating gastric cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.
- EGFR bispecific anti-epidermal growth factor receptor
- c-Met hepatocyte growth factor receptor
- the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6, and wherein the second domain that binds c-Met comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
- HCDR1 heavy chain complementarity determining region 1
- LCDR2 of SEQ ID NO: 2
- EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
- the bispecific anti-EGFR/c- Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
- HC1 first heavy chain
- LC1 first light chain
- HC2 second heavy chain
- LC2 second light chain
- LC2 second light chain
- the chemotherapy comprises a fluoropyrimidine -based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof.
- the fluoropyrimidine is 5 -fluorouracil or capecitabine.
- a method of treating esophageal cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.
- EGFR bispecific anti-epidermal growth factor receptor
- c-Met hepatocyte growth factor receptor
- the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met
- the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6,
- the second domain that binds c-Met comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
- the bispecific anti- EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
- the chemotherapy comprises a fluoropyrimidine -based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof.
- Example 1 A Phase 2, Open-label Study of Amivantamab in Subjects with Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
- GCs Gastric cancers
- ECs esophageal cancer
- EGFR and cMet the expression of these proteins have corelated with poor prognosis.
- many agents targeting EGFR are part of standard of care for many tumor types, no anti-EGFR or anti-cMet therapy has been approved in GC or EC.
- amivantamab As a bispecific duobody capable of engaging the extracellular domains of both EGFR and cMet receptors, amivantamab has a unique mechanism of action that suggests it has the potential to control EGFR-expressed and/or cMet-expressed GC and EC patients.
- Amivantamab has demonstrated in vitro and in vivo pre-clinical activities against tumors with the EGFR or cMet amplified GC and EC models (Vijayaraghavan 2020). Furthermore, clinical experience of amivantamab in NSCLC has shown clinical benefit against broad-spectrum of EGFR and cMet aberrations, including EGFR protein overexpression and cMet amplifications.
- This study aims to evaluate the clinical activity of amivantamab as a monotherapy in GC (including GEJ cancer) and EC patients who had received at least 2 prior lines (GC/GEJ participants) or 1 prior line (EC participants) of standard therapy.
- the Phase 2a cohorts aim to initially investigate the anti-tumor activity of amivantamab in participants with documented expression of either EGFR, cMet, or both as evaluated by immunohistochemistry (IHC). Approximately 30 participants with any expression level of EGFR, cMet, or both proteins are enrolled in each of the Phase 2a cohort.
- Phase 2a cohorts investigate the clinical activity of amivantamab in selected patient population based on the Phase 2a data.
- Table 1 Schedule of Activities for Study Procedures/Assessments
- AE reverse event
- C Cycle
- ctDNA circulating tumor DNA
- CT computerized tomography
- cMet tyrosine-protein kinase mesenchymal-epithelial transition
- D Day ;
- ECG electrocardiogram
- ECOG Eastem Cooperative Oncology Group
- EGFR epidermal growth factor receptor
- EoT end-of-treatment
- FU follow-up
- HBV hepatitis B virus
- HCV hepatitis C virus
- HIV human immunodeficiency virus
- h hour
- ICF informed consent form
- IHC Immunohistochemistry
- Dose modification guidance is provided to manage toxicities that occur during the study (refer to Dose Delay Guidance Section and Dose Modification Guidance Section), including specific guidance for infusion-related reactions (IRRs), rash, interstitial lung disease (ILD), liver test abnormalities, or paronychia.
- IRRs infusion-related reactions
- ILD interstitial lung disease
- liver test abnormalities or paronychia.
- Amivantamab is generally safe and well tolerated based on the data mentioned above.
- Amivantamab is expected to exhibit anti-tumor activity in participants with GC or EC expressing any level of EGFR, cMET, or both proteins.
- Phase 2b GC or EC expansion cohorts may be initiated to evaluate the antitumor activity of amivantamab in selected GC and EC participants based upon the prospective assessment of IHC during Phase 2a ( Figure 1).
- a maximum of approximately 282 participants are enrolled in the combined Phase 2a and Phase 2b populations, in the event the efficacy observed in both Phase 2a cohorts warrants full enrollment in their respective Phase 2b cohorts.
- Approximately, 30 response evaluable participants are enrolled in each of Phase 2a GC and EC arm.
- at least 20 participants expressing IHC 2+ or higher are enrolled.
- Phase 2a At least 10 participants expressing any level of cMet protein (IHC1+ or above) are enrolled in each Phase 2a cohort to better characterize the contribution of cMet in amivantamab activity. Additional enrollment may be allowed in the Phase 2a cohorts to achieve this minimal enrollment, if these criteria aren’t met in the initial 30 evaluable subjects. If activity is demonstrated in the Phase 2a cohorts, Phase 2a expansion cohorts investigating a maximum of 11 participants without any expression of EGFR and cMet, may open for enrollment. The Phase 2b GC expansion or EC expansion cohorts evaluate the antitumor activity of amivantamab in GC and EC patients, using biomarker selection based upon Phase 2a results. If activated, approximately 100 participants are enrolled in each of the Phase 2b cohorts.
- the study includes a screening phase (Screening Phase (Pre- and Full Screening) Section), a treatment phase (Treatment Phase Section), and a follow-up phase (Follow-up Phase (Applicable to Phase 2b Only) Section).
- the treatment phase for a participant begins on C1D1 and continue as 28-day cycles until the end-of-treatment (EOT) visit, approximately 30 days after discontinuation of study treatment.
- EOT end-of-treatment
- This study is conducted in an outpatient setting.
- in-hospital observation from C1D1 until C1D8 is permitted in the Phase 2a (including Phase 2a extension cohorts) to allow close monitoring.
- Study treatment continues until documented clinical or radiographic (RECIST Version 1.1) disease progression or until the participant meets another criterion for discontinuation of study treatment.
- the recommended Phase 2 dose was determined to be 1050 mg for body weight ⁇ 80 kg and 1400 mg for body weight >80 kg, administered by IV infusion in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles.
- the recommended Phase 2 dose achieved a complete soluble target saturation throughout dosing for the EGFR and cMet in the lung cancer participants.
- amivantamab The observed safety profile of amivantamab is consistent with EGFR and cMet inhibition and majority of treatment emergent adverse events (TEAEs) were Grade 1 to 2 in severity. Therefore, administering the same dosing regimen to GC or EC participants is considered appropriate.
- Participant is >20 years of age (or the legal age of consent in the jurisdiction in which the study is taking place).
- Participant tumor express either EGFR, cMet, or both as determined by either local or central IHC assay (IHC 1+ or above). A copy of the de-identified pathology report for IHC analysis is submitted during the screening period if local IHC test was used for the eligibility determination.
- Phase 2a extension cohorts Participant tumor lacks expression of EGFR and MET as determined by either local or central IHC assessment. A copy of the de-identified pathology report for IHC analysis is submitted during the screening period if local IHC test was used for the eligibility determination.
- Participant has histologically or cytologically confirmed gastric (including GEJ) or EC that is locally advanced, unresectable, or metastatic, and not eligible for curative treatment.
- Prior therapies include fluoropyrimidine-, and platinum-based chemotherapy (including chemoradiation therapy given as stage IV setting), (b) Participant who underwent a radical resection in conjunction with chemotherapy including neo- adjuvant/adjuvant therapy and chemoradiation (including participants who underwent chemoradiation, if residual tumor exists, followed by salvage surgery) whose recurrence was confirmed by imaging within 24 weeks after the last dose of chemotherapy are considered as having received 1 line of prior systemic therapy for the purpose of meeting the eligibility criteria.
- prior combination therapy discontinued due to an AE, and then one of the agents continued, this is considered to be “1 prior line” and not “2 prior lines.”
- the change in dosage form (IV administration, oral administration) or dose reduction without progression is considered to be “1 prior line” and not “2 prior lines.”
- Participant has measurable disease according to RECIST Version 1.1. If only one measurable lesion exists, it may be used for the screening biopsy if the baseline tumor assessment scans are performed >7 days after the biopsy.
- Participant has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Eastern Cooperative Oncology Group (ECOG) Performance Status).
- ECOG Eastern Cooperative Oncology Group
- Participant has adequate organ and bone marrow function as follows, without history of red blood cell transfusion or platelet transfusion within 7 days prior to the date of the laboratory test. a. Hemoglobin >8 g/dL b. Absolute neutrophil count >1500/mm 3 , without use of granulocyte colony stimulating factor (G-CSF) within 10 days prior to the date of the test c. Platelets >75,000/mm 3 d. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
- Participant has a tumor lesion amenable for biopsy and agree to protocol-defined mandatory biopsies.
- Participant has an uncontrolled illness, including but not limited to the following: a. Diabetes b. Ongoing or active bacterial infection (includes infection requiring treatment with antimicrobial therapy [participants are required to complete antibiotics 1 week before enrollment]), symptomatic viral infection, or any other clinically significant infection c. Active bleeding diathesis d. Psychiatric illness/social situation that would limit compliance with study requirements [00283] 2. Participant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or 4 half-lives whichever is longer or had radiation therapy within 4 weeks before the first administration of study treatment. For agents with long half-lives, the maximum required time since last dose is 28 days.
- Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia or post-radiation skin changes [any grade], Grade ⁇ 2 peripheral neuropathy, and Grade ⁇ 2 hypothyroidism stable on hormone replacement).
- Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and of corticosteroid treatment for at least 2 weeks prior to the first administration of study treatment is eligible), history of leptomeningeal disease or spinal cord compression that has not been treated definitively with surgery or radiation. If brain metastases are diagnosed on screening imaging, the participant may be rescreened for eligibility after definitive treatment.
- Participant has a history of(non-infectious) ILD/pneumonitis that required steroids, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Esophageal cancer participants with history of completely resolved radiation pneumonitis (defined as radiographically stable for 3 months prior to enrollment without need of any treatment) may be enrolled.
- Participant has an active malignancy (i.e., progressing or requiring treatment change in the last 12 months) other than the disease being treated under study. The only allowed exceptions are: a. Non-muscle invasive bladder cancer treated within the last 24 months that is considered completely cured. b. Skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured. c. Non-invasive cervical cancer treated within the last24 months thatis considered completely cured. d. Localized prostate cancer (N0M0):
- Clinically nonsignificant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary.
- Congestive heart failure defined as New York Heart Association (NYHA) class III-IV or Hospitalization for congestive heart failure (any NYHA class) (New York Heart Association Criteria) within 6 months of study enrollment.
- Pericarditis/clinically significant pericardial effusion. f. Myocarditis.
- Participant has known allergies, hypersensitivity, or intolerance to excipients of amivantamab.
- Participant has, or is expected to have, any of the following: a. An invasive operative procedure with entry into a body cavity, within 4 weeks or without complete recovery before C1D1. Thoracentesis, if needed, and percutaneous biopsy for basefine tumor tissue sample may be done less than 4 weeks prior to CID 1, as long as the participant has adequately recovered from the procedure prior to the first dose of study treatment in the clinical judgement of the investigator b. Significant traumatic injury within 3 weeks before the start of C1D1 (unless all wounds are fully healed prior to Day 1 ) c. Expected major surgery while the investigational agent is being administered or within
- Participant has at screening: a. Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg). Participants with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at screening 1) a negative HBsAg and 2) an HBV DNA (viral load) below the lower limit of quantification, per local testing. Participants with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing. b. Positive hepatitis C antibody (anti-HCV [hepatitis C virus]). Participants with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible. c. Other clinically active infectious or non-infectious fiver disease
- Participant is known to be positive for human immunodeficiency virus (HIV), with
- ART highly active antiretroviral therapy
- ART highly active antiretroviral therapy
- c Receiving ART that may interfere with study treatment
- CD4 count ⁇ 350 at screening
- AIDS Acquired immunodeficiency syndrome
- Amivantamab is supplied for this study in a glass vial containing 350 mg/vial with concentration of 50 mg/mL in a 7 mL vial.
- the IV infusion is prepared at the site in 250 mL of diluent.
- the initial dosage of amivantamab is based on the participant's body weight at screening: 1,050 mg (if body weight is ⁇ 80 kg) or 1,400 mg (if body weight is >80 kg), s Amivantamab is administered as an IV infusion in 28-day cycles as follows:
- Cycle 1 Once weekly (with the first dose split over Day 1 [350 mg] and Day 2 [700 mg if body weight is ⁇ 80 kg or 1,050 mg if body weight is >80 kg]).
- Cycles 2+ Days 1 and 15 of each cycle.
- Cycle 1 Once weekly (with the first dose split over Day 1 [350 mg] and Day 2 [ 1400 mg if body weight is ⁇ 80 kg or 1,750 mg if body weight is >80 kg]).
- Cycles 2+ Days 1 and 15 of each cycle.
- Amivantamab is administered intravenously using an escalating infusion rate regimen.
- the product is infused via a peripheral vein for all Cycle 1 doses; infusion via central line is allowed for subsequent dosing starting with the C2D1 dose.
- Amivantamab is administered according to clinical protocol. Additional guidance is provided below:
- Amivantamab is not mixed or diluted with other drugs.
- Amivantamab is not administered as an IV push or bolus.
- Dose and administration schedule may be adjusted during this study.
- Randomization is not used in this study. Participants are assigned to treatment in the order in which they qualify for this study.
- treatment with amivantamab may be delayed until recovery of toxicity to a level allowing continuation of therapy.
- a participant for whom treatment was delayed is assessed at least weekly to ensure adequate supportive care is being administered and to assess for improvement of toxicity.
- Dose Modification Guidance Section For majority of clinically significant toxicities withholding doses and dose modifications may be made as per the guidelines described below (Dose Modification Guidance Section).
- participant are clinically monitored at regular intervals (including an assessment prior to the start of infusion).
- the monitoring includes heart rate, blood pressure, temperature, respiratory rate, and oxygen saturation measurements.
- Participants for whom required medications are contraindicated may explore alternative medications with their study physician. If alternative medications are not suitable for the intent above, participants are not required to take the corresponding medication.
- optional predose steroids may be administered if clinically indicated for participants who experiencedaninfusion-relatedreactiononClDl orC!D2.
- Optional amivantamab post-infusion medications may be prescribed and continued for up to 48 hours after the infusion if clinically indicated as described in Table 4.
- IV intravenous .
- Optional medications can be used prophylactically as clinically indicated. If a medication noted in this table is not locally available, a similar medication and dose may be substituted and administered per local guidelines Prohibited or Restricted Medications and Therapies
- Radiotherapy to tumor lesions being assessed for tumor response prior to radiographic progression
- the total blood volume collected for the study is approximately 25 mL (screening), 105 mL (Cycle 1), 75 mL (Cycle 2), and 30 mL (for each cycle beyond Cycle 3 and EOT).
- the baseline disease assessments are performed as close as possible to the start of treatment, but no more than 28 days prior to the first dose. Subsequent assessments are performed at 6 weeks (+ 1 week) after initiation of study treatment administration, then every 6 weeks ( ⁇ 1 week) for the first 12 months and then every 12 weeks ( ⁇ 1 week) until objective radiographic disease progression. Timing for each disease assessment is relative to the first dose of study treatment administration, regardless of dose modifications, and continues until disease progression. Any other site at which new disease is suspected is also imaged.
- Radiographic progression is documented even after discontinuation of treatment for symptomatic deterioration, but prior to subsequent therapy, if possible.
- tumor assessments is continued per schedule until radiographic progressive disease is documented.
- the study includes the following evaluations of safety and tolerability according to the time points provided in the Schedule of Activities Section.
- the screening physical examination includes, at a minimum, the participant’s height, weight, and general appearance and an examination of the skin, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system.
- the participant On Day 1 of each cycle, directed physical examinations of involved organs and other body systems, as indicated, are performed and participant body weight is obtained using a calibrated scale.
- Blood pressure and heart rate measurements are assessed in a seated position with a completely automated device. Manual techniques are used only if an automated device is not available.
- Blood pressure and heart rate measurements are preceded by at least 5 minutes of rest in a quiet setting without distractions (e.g., television, cell phones).
- distractions e.g., television, cell phones.
- ECGs Triplicate electrocardiograms
- Participants are in a quiet setting without distractions (e.g., television, cell phones). Participants rest in a supine position for at least 5 minutes before ECG collection and are refrain from talking or moving arms or legs. If blood sampling or vital sign measurement is scheduled for the same time point as ECG recording, the procedures are performed in the following order: ECG(s), vital signs, blood draw.
- ECG(s) Three individual ECG tracings are obtained as closely as possible in succession, but approximately 2 minutes apart. The ECG, including ECG morphology, is reviewed for immediate management.
- QTcF QT/(RR) A 0.33.
- Eastern Cooperative Oncology Group performance status score is evaluated during the screening phase to determine the eligibility.
- Clinical laboratory assessments are performed locally. Clinical laboratory tests are performed as noted in Table 5.
- More frequent clinical laboratory tests may be performed as indicated by the overall clinical condition of the participant or abnormalities that warrant more frequent monitoring.
- Blood samples are used to evaluate the PK of amivantamab. Serum collected for PK may additionally be used to evaluate safety or efficacy aspects that address concerns arising during or after the study period. Evaluations
- Blood samples are collected for measurement of serum amivantamab for PK analyses.
- the PK profile of amivantamab is based on serum concentration data obtained from the timepoints surrounding the first and fifth dose administrations collected from at least 10 participants in each cancer type in Phase 2a.
- Blood samples for sparse PK is also obtained following all other dose administrations from participants in Phase 2a and 2b, prior to the start of the infusion and following the end of the infusion, from all the participants. Analytical Procedures
- serum PK samples may be stored for future analysis of other coadministered treatments.
- the primary PK endpoints include, but are not limited to maximum serum concentration (Cmax), T m ax, AUC(ti-t2) (e.g., AUCoayi-s), AUCtau, plasma/serum concentration immediately prior the next study treatment administration (Ctrough), ti/2, CL, steady state volume of distribution (Vss), and accumulation ratio.
- Cmax maximum serum concentration
- T m ax T m ax
- AUC(ti-t2) e.g., AUCoayi-s
- AUCtau plasma/serum concentration immediately prior the next study treatment administration
- Ctrough plasma/serum concentration immediately prior the next study treatment administration
- ti/2 ti/2
- CL steady state volume of distribution
- accumulation ratio accumulation ratio
- Biomarkers Collected tumor tissue samples are used to evaluate the tumor surface levels of EGFR and cMET protein expression by centrally performed IHC assay to determine the patient eligibility, although documentation of previously performed local IHC results may be submitted for the purposes of demonstrating eligibility for study conduct. All statistical and biomarker analysis, however, utilize the results of the centrally performed IHC results, which classify patients as 0, 1+, 2+ or 3+ based on the highest staining of either EGFR or cMet. Tumor tissue collected at screening may also be analyzed by tumor next-generation sequencing to evaluate molecular alterations and track response to treatment. Tumor samples collected post-treatment and post-progression may also be evaluated by IHC and next-generation sequencing to track response to amivantamab. Tissues may also be used to determine biomarkers relevant to GC/EC and/or analyzed to confirm ctDNA results.
- Blood samples are also collected at time points and may be analyzed for circulating factors relevant to disease biology (e.g., hepatocyte growth factor).
- factors relevant to disease biology e.g., hepatocyte growth factor
- Blood samples are also collected from at least 10 participants in each cancer type at selected time points to analyze PD markers (e.g., soluble EGFR and cMet) in samples taken prior to and after exposure to amivantamab, to explore whether the complete soluble target saturation throughout the dosing was attained.
- PD markers e.g., soluble EGFR and cMet
- FFPE formalin-fixed, paraffin-embedded
- Serum samples are collected for immunogenicity assessments of amivantamab (antidrug antibodies to amivantamab).
- the detection and characterization of antibodies to amivantamab is performed using a validated immunoassay method.
- Serum samples are screened for antibodies binding to amivantamab and serum titer is determined from positive samples. Antibodies may be further characterized and/or evaluated for their ability to neutralize the activity of the study treatment. All samples collected for immune response analysis are also evaluated for amivantamab serum concentration to ensure appropriate interpretation of immunogenicity data. Other immunogenicity analyses may be performed to further characterize any immune responses generated.
- Phase 2a approximately 30 response evaluable participants with tumors expressing either EGFR, cMet, or both, as determined by central IHC, are enrolled in GC and EC cohorts. Twenty participants are enrolled for IHC 2+/3+ that provides approximately 90% probability to observe the posterior probability of (ORR >22.5%) >40% (which is similar with ORR >20%) assuming ORR is 30% for the subpopulation. By enrolling 10 participants with IHC 1+, the probability to observe the posterior probability (ORR >22.5%) >40% is 80%. A maximum of 11 participants may be enrolled in each Phase 2a extension cohort.
- Enrollment halts if no response or stable disease of 6 weeks or more is observed among the first 6 participants for futility in each of the Phase 2a extension cohorts. If 2 or more responses are observed in each of Phase 2a extension cohorts, Additional participants may be enrolled for further characterization.
- Immunogenicity population All participants who receive at least 1 dose of study treatment and have at least 1 evaluable post-baseline measurement.
- Intercurrent event subsequent anticancer therapy.
- the while-on-treatment policy Response after this intercurrent event is not included.
- the primary efficacy measure is ORR.
- Objective response rate is defined as the proportion of participants who achieve either CR or PR, determined by investigator assessment using RECIST Version 1.1. Confirmation of investigator-assessed ORR may be performed through IRC in the Phase 2b.
- Disease Control Rate Disease control rate is defined as the percentage of participants achieving complete or partial response or stable disease for at least 6 weeks as defined by RECIST Versionl.l. The DCR and its 95% CI with Clopper-Pearson method are also calculated.
- Duration of Response Duration of Response (DoR) is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first. The end of response would coincide with the date of progression or death from any cause used for the PFS endpoint. If a participant does not progress following a response, then his/her duration of response uses the PFS censoring time. A Kaplan-Meier plot and median DoR with 95% confidence interval (calculated from the Kaplan-Meier estimate) are presented. Confirmation of investigator-assessed DoR may be performed through IRC in the Phase 2b.
- Progression-free survival is defined as the time from first dose until the date of objective disease progression or death (by any cause in the absence of progression), whichever comes first, based on investigator assessment using RECIST Version 1.1. Participants who have not progressed or have not died at the time of analysis are censored at the time of the latest date of assessment from their last evaluable RECIST Version 1.1 assessment. PFS is analyzed using the same methodology as for the analysis of DoR.
- Overall survival is defined as the time from the date of first dose until the date of death due to any cause. Any participant not known to have died at the time of analysis are censored based on the last recorded date on which the participant was known to be alive. OS is analyzed using the same methodology as for the analysis of DoR.
- PK analyses use the PK population. Serum amivantamab concentrations are summarized for each cancer type and overall population in tables of mean, SD, median, and range over time, as appropriate. PK parameters are estimated for individuals and descriptive statistics are calculated for each cancer type and overall population.
- Participants are excluded from the PK analysis if their data do not allow for accurate assessment of the PK (e.g., incomplete administration of the study treatment; missing information of dosing and sampling times; concentration data not sufficient for PK parameter calculation).
- Serum samples are screened for antibodies binding to amivantamab and the number of confirmed positive samples are reported. Other analyses may be performed to further characterize the immunogenicity of amivantamab.
- biomarker analyses use the biomarker population. Analyses are planned to explore PD and other biomarkers that may be indicative of the mechanisms of action of the drug or predictive of efficacy as well as the potential mechanisms of resistance to amivantamab. [00369] The association of biomarker-positivity with clinical response or time-to-event endpoints is assessed using statistical methods appropriate for each endpoint (eg, analysis of variance, categorical, or survival models). Correlation of baseline biomarker expression levels with clinical response or relevant time to-event endpoints is performed to identify responsive (or resistant) subgroups.
- Additional biomarkers DNA, RNA, and/or protein
- DNA, RNA, and/or protein relevant to GC/EC may also be assessed in blood and tissue samples collected during the study to better understand the disease and mechanisms of response or resistance to amivantamab.
- Phase 2b an interim futility analysis is planned in each of GC and EC arm approximately 12 weeks after 50 participants receive the first infusion.
- the interim futility analyses is based on the best response rate for each subpopulation (for example, IHC 2+/3+ and IHC 1+) selected at the end of Phase 2a and prespecified before initiating Phase 2b).
- the enrollment of each subpopulation may be terminated for futility if the posterior probability (ORR >22.5%) is ⁇ 40%.
- the “All Treated” patient population were patients who received at least 1 dose of study treatment.
- the “Response Evaluable” patient population were patients who ( 1 ) received at least 1 dose of study treatment, (2) met all eligibility criteria for the study, and (3) had a baseline and at least 1 post-baseline efficacy disease assessments, or have disease progression/death due to disease progression prior to the first post-baseline disease assessment.
- Table 10 shows summary of objective response rate based on RECIST Version 1.1 criteria by pre-screening IHC Score (Central) in response evaluable population.
- Table 11 shows summary of objective response rate based on RECIST Version 1.1 criteria by pre-screening IHC score (Central) in all treated population.
- Table 10 Summary of Objective Response Rate Based on RECIST Version 1.1 Criteria by Pre-screening IHC Score (Central) - Investigator Judgement (Response evaluable population)
- CI confidence interval a For a response to qualify as stable disease, follow-up measurements must have met the stable disease criteria at least once at a minimum interval >6 weeks after the first dose of study agent. b The exact Clopper-Pearson 95% CI is used. c The Posterior probability (ORR >22.5%) is calculated based on beta distribution.
- IHC score is defined as the highest staining of either EGFR or cMet.
- CI confidence interval a For a response to qualify as stable disease, follow-up measurements must have met the stable disease criteria at least once at a minimum interval >6 weeks after the first dose of study agent, b The exact Clopper-Pearson 95% CI is used. c The Posterior probability (ORR >22.5%) is calculated based on beta distribution.
- IHC score is defined as the highest staining of either EGFR or cMet.
- the overall response for gastric cancer patients in response evaluable population is shown in Figure 6.
- the overall response for gastric cancer patients in all treated population is shown in Figure 7.
- the overall response for esophageal cancer patients in response evaluable population is shown in Figure 8.
- the overall response for esophageal cancer patients in all treated population is shown in Figure 9.
- Example 2 Evaluation of amivantamab in esophageal patient-derived xenograft models (PDX) models expressing wild-type EGFR
- the study endpoints were to compare the tumor growth in each group at the end of treatments, and the subsequent tumor outgrowth after dosing stopped.
- the tumor growth curves (expressed as Mean ⁇ SEM) over time are shown in Figures 2A-2L.
- Example 3 Evaluation of amivantamab single agent or in combination with chemo-drugs or capmatinib in the treatment of gastric PDX tumors
- a panel of gastric PDX models were selected for treatment with amivantamab alone, or in combination with c-Met inhibitor capmatinib (Selleck), as well as gastric chemo-regimens, such as 5-FU (Shanghai Xudong Haipu Pharm) plus cisplatin (Qilu Pharm), or paxlitaxel (Beijing Union Pharm).
- c-Met inhibitor capmatinib Selleck
- gastric chemo-regimens such as 5-FU (Shanghai Xudong Haipu Pharm) plus cisplatin (Qilu Pharm), or paxlitaxel (Beijing Union Pharm).
- Tumor fragments from stock tumor bearing mice were harvested and inoculated into BALB/c nude mice. Each mouse was inoculated subcutaneously in the right flank with indicated tumor fragments (2-3 mm in diameter) for tumor development.
- Detailed gastric PDX information is listed in Table 17.
- the tumor growth was measured twice weekly. Once the mean tumor volume reached approximate 150 mm 3 , animals were randomly allocated to relevant study groups with 8 mice per group. The randomization was performed according to the tumor size of each group, and the day of randomization was denoted as DayO. The treatments were started on the same day of randomization according to the dosing regimen in Table 18 where appropriate.
- QW once weekly; BIW: twice weekly (DayO, 3 per week); BID: twice daily with 12 hours interval; QD, 5 days/week: once daily from DayO-5 per week.
- GA0046 was treated with group 1,2, 7, 8; GA0075 and GA0152 were treated with group 1-6 (15 mg/kg paclitaxel); GA3121 was treated with group 1,2, 5, 6 (10 mg/kg paclitaxel); GA2254 and GA3236 were treated with group 1-2.
- the study endpoints were to compare the tumor growth in each group at the end of treatments, and the subsequent tumor outgrowth after dosing stopped.
- Tumor growth curves (expressed as Mean ⁇ SEM) over time are shown in Figures 3A-3F.
- amivantamab mono-treatment (10 mg/kg BIW) inhibited tumor growth in 3 out of 6 PDX models with strong anti-tumor activity observed in GA0046 (TGI% 121.31%) and GA0075 (101.17%).
- H-Score (0-300) (%@0) x 0 + (%@1) X 1 + (%@2) x 2 + (%@3) X 3 %@0: percentage of cells with intensity 0 (negative staining).
- %@ 1 percentage of cells with intensity 1+ (weak or incomplete membrane staining).
- %@2 percentage of cells with intensity 2+ (weak-to-moderate complete membrane staining).
- %@3 percentage of cells with intensity 3+ (strong complete membrane staining).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure provides methods of treating gastric or esophageal cancer in a subject in need thereof by administering a therapeutically effective amount of a bispecific anti- epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.
Description
USE OF ANTI-EGFR/ANTI-MET ANTIBODY TO TREAT GASTRIC OR ESOPHAGEAL CANCER
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0001] The sequence listing of the present application is submitted electronically via The United States Patent and Trademark Center Patent Center as an XML formatted sequence listing with a file name “JBI6733WOPCTlSEQLIST.xml”, creation date of June 28, 2023, and a size of 20 kilobytes (KB). This sequence listing submitted is part of the specification and is herein incorporated by reference in its entirety.
FIELD
[0002] The present disclosure relates to methods of treating gastric or esophageal cancer with a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c- Met) antibody.
BACKGROUND
[0003] Cancer is a leading cause of death worldwide. Gastric cancer (GC) is the fifth most common cancer worldwide and over 1 million new cases were reported worldwide in 2018. Gastric cancer is highly prevalent in Asian countries accounting for approximately 75% of new cases in 2018 and is the third (male)/fourth (female) most prevalent cancer in Japan. Majority of patients exhibit adenocarcinoma histology. The treatment regimen depends on the type of cancer (e.g., histology), the stage of the cancer at diagnosis, and the presence of molecular biomarkers (e.g., human epidermal growth factor receptor 2 (HER2) amplification, programmed deathligand 1 (PD-L1) expression, and microsatellite instability). Treatment commonly includes surgery and chemotherapy. In patients with metastatic disease, National Comprehensive Cancer Network (NCCN) guidelines recommend HER2, programmed death-ligand 1 (PD-L1), and microsatellite instability testing (NCCN Guidelines 2020). The first line treatment generally includes fluoropyrimidine plus cisplatin or oxaliplatin plus trastuzumab (depending on HER2 status). The observed overall response rate for the guideline-recommended initial treatment varies widely (e.g., between 35% to 68% for the combination therapy with oral fluoropyrimidine
(S-l) in Japan (Bang 2010; Kurokawa 2014)). Available treatment options after first line treatment are limited. The NCCN recommendations are chemotherapy as a single agent, ramucirumab plus paclitaxel, immune checkpoint inhibitor, or fluorouracil plus irinotecan. However, the overall response rate for the second and third line treatments is limited and the median progression-free survival is very low.
[0004] Esophageal cancer (EC) is the eighth most common cancer worldwide and ranked sixth among all cancers in mortality in 2018. Similar to GC, EC is highly prevalent in Asian countries accounting for over 75% of new cases in 2018. Squamous cell carcinoma and adenocarcinoma are two major histologies of primary ECs. However, predominant EC histology varies between geographical regions. The predominant histology observed among the Caucasian population is adenocarcinoma whereas squamous histology predominates Asian countries. Treatment commonly includes surgery, radiation therapy, chemoradiation therapy, and chemotherapy. The NCCN guideline recommendations for the first line therapies are identical to GC regimens due to the nature of histological similarities (NCCN Guidelines 2020). Clinical data of esophageal squamous cell carcinoma, which is the predominant histology in Asian countries, are limited to mostly Phase 2 studies. The reported overall response rate of chemotherapy as a single agent is 15%~40%. Other recommended treatments include fluorouracil plus cisplatin and PD-(L)1 inhibitor, pembrolizumab. Yet, the observed overall response rates to these therapies are quite limited.
[0005] As such, there is an unmet need in the art for improved therapies for the treatment of gastric or esophageal cancer.
SUMMARY
[0006] In various aspects, provided herein are methods of treating gastric or esophageal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.
[0007] In one aspect, the present disclosure provides a method of treating gastric cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
[0008] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6, and wherein the second domain that binds c-Met comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
[0009] In some embodiments of the method for treating gastric cancer, the first domain that specifically binds EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
[0010] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody is an IgGl isotype.
[0011] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
[0012] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody comprises a biantennary glycan structure with a fucose content of about between 1% to about 15%.
[0013] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody is administered intravenously or subcutaneously to the subject.
[0014] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 3400 mg. [0015] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 350 mg, 700 mg, about 750 mg, about 800 mg, about 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, 2000 mg, 2100 mg, 2200 mg, 2240 mg, 2300
mg, 2400 mg, 2500 mg, 2600 mg, 2700 mg, 2800 mg, 2900 mg, 3000 mg, 3100 mg, 3200 mg, 3300 mg, 3360 mg, or 3400 mg.
[0016] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody is administered at a dose of 1050 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1600 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1750 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg.
[0017] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody is administered subcutaneously or intradermally to the subject. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally at a dose sufficient to achieve a therapeutic effect in the subject.
[0018] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody is administered intravenously to the subject. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered intravenously at a dose sufficient to achieve a therapeutic effect in the subject.
[0019] In some embodiments of the method for treating gastric cancer, the bispecific anti- EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter. In some embodiments, the first dose of the bispecific anti-EGFR/c-Met antibody is administered over two days.
[0020] In some embodiments of the method for treating gastric cancer, one or more cells of the gastric cancer express EGFR and/or cMet.
[0021] In some embodiments of the method for treating gastric cancer, the subject has received a prior treatment. In some embodiments, the prior treatment comprises a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a
combination thereof. In some embodiments, the chemotherapy comprises a fluoropyrimidine- based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof. In some embodiments, the fluoropyrimidine is 5 -fluorouracil or capecitabine. In some embodiments, the platinum-based chemotherapy is cisplatin, oxaliplatin, carboplatin, or nedaplatin. In some embodiments, the targeted therapy comprises an anti-HER2 therapy or anti- VEGF/VEGFR therapy. In some embodiments, the anti-HER2 therapy comprises trastuzumab. In some embodiments, the anti-VEGF/VEGFR therapy comprises bevacizumab or ramucirumab. [0022] In some embodiments of the method for treating gastric cancer, the method further comprises administering at least one additional therapeutic to the subject. In some embodiments, the additional therapeutic comprises a glucocorticosteroid, antihistamine, antipyretic, H2- antagonist, antiemetic, opiate, or any combination thereof.
[0023] In some embodiments of the method for treating gastric cancer, the gastric cancer is an advanced or metastatic cancer.
[0024] In some embodiments of the method for treating gastric cancer, the subject is human. [0025] In one aspect, the present disclosure provides a method of treating esophageal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
[0026] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6, and wherein the second domain that binds c-Met comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
[0027] In some embodiments of the method for treating esophageal cancer, the first domain that specifically binds EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
[0028] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody is an IgGl isotype.
[0029] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
[0030] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody comprises a biantennary glycan structure with a fucose content of about between 1% to about 15%.
[0031] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody is administered intravenously or subcutaneously to the subject.
[0032] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 3400 mg.
[0033] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 350 mg, 700 mg, about 750 mg, about 800 mg, about 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, 2000 mg, 2100 mg, 2200 mg, 2240 mg, 2300 mg, 2400 mg, 2500 mg, 2600 mg, 2700 mg, 2800 mg, 2900 mg, 3000 mg, 3100 mg, 3200 mg, 3300 mg, 3360 mg, or 3400 mg.
[0034] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody is administered at a dose of 1050 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1600 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1750 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg.
[0035] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody is administered subcutaneously or intradermally to the subject. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally at a dose sufficient to achieve a therapeutic effect in the subject.
[0036] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody is administered intravenously to the subject. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered intravenously at a dose sufficient to achieve a therapeutic effect in the subject.
[0037] In some embodiments of the method for treating esophageal cancer, the bispecific anti- EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter. In some embodiments, the first dose of the bispecific anti-EGFR/c-Met antibody is administered over two days.
[0038] In some embodiments of the method for treating esophageal cancer, one or more cells of the esophageal cancer express EGFR and/or cMet.
[0039] In some embodiments of the method for treating esophageal cancer, the subject has received a prior treatment. In some embodiments, the prior treatment comprises a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a combination thereof. In some embodiments, the chemotherapy comprises a fluoropyrimidine- based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof. In some embodiments, the fluoropyrimidine is 5 -fluorouracil or capecitabine. In some embodiments, the platinum-based chemotherapy is cisplatin, oxaliplatin, carboplatin, or nedaplatin. In some embodiments, the targeted therapy comprises an anti-HER2 therapy or anti- VEGF/VEGFR therapy. In some embodiments, the anti-HER2 therapy comprises trastuzumab. In some embodiments, the anti-VEGF/VEGFR therapy comprises bevacizumab or ramucirumab. [0040] In some embodiments of the method for treating esophageal cancer, the subject is treatment naive.
[0041] In some embodiments of the method for treating esophageal cancer, the method further comprises administering at least one additional therapeutic to the subject. In some embodiments,
the additional therapeutic is a glucocorticosteroid, antihistamine, antipyretic, H2-antagonist, antiemetic, opiate, or any combination thereof.
[0042] In some embodiments of the method for treating esophageal cancer, the esophageal cancer is an advanced or metastatic cancer.
[0043] In some embodiments of the method for treating esophageal cancer, the subject is human.
BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 depicts one aspect of the Phase 2 study described in Example 1.
[0045] Figures 2A-2L show tumor growth curves (expressed as Mean ± SEM) over time in a series of esophageal patient-derived xenografts (PDX) models.
[0046] Figures 3A-3F show tumor growth curves (expressed as Mean ± SEM) over time in a series of gastric PDX models.
[0047] Figure 4 shows relative EGFR and c-Met H-scores together with anti-tumor activity of amivantamab in a series of esophageal PDX models.
[0048] Figure 5 shows relative EGFR and c-Met H-scores together with anti-tumor activity of amivantamab in a series of gastric PDX models.
[0049] Figure 6 shows the overall response for gastric cancer patients in response evaluable population.
[0050] Figure 7 shows the overall response for gastric cancer patients in all treated population.
[0051] Figure 8 shows the overall response for esophageal cancer patients in response evaluable population.
[0052] Figure 9 shows the overall response for esophageal cancer patients in all treated population.
[0053] Figure 10 shows the overall response for esophageal cancer in patients treated with 1750 mg amivantamab in response evaluable population.
DETAILED DESCRIPTION
[0054] Receptor tyrosine kinases (RTK) are involved in the regulation of many processes in mammalian development, cell function, and tissue homeostasis. Dysregulation of RTKs has been
implicated in the development of numerous human cancers, and various RTKs are targets for both approved and experimental anticancer therapies.
[0055] Epidermal growth factor receptor (EGFR), an RTK in the HER family, is normally expressed in tissues of epithelial, mesenchymal, and neuronal origin. Binding of any of its 7 ligands, including EGF, induces diverse cellular responses, including differentiation, proliferation, migration, and survival (Olayioye 2000). The mesenchymal-epithelial transition factor (cMet or MET) receptor is also an RTK, expressed in normal epithelial cells (Prat 1991), with a role in growth and homeostasis, including embryonic development, angiogenesis, and wound healing (Sattler 2011). cMet is activated by a single specific ligand, hepatocyte growth factor, also known as scatter factor.
[0056] Overexpression and mutations of the EGFR and cMet receptors have been linked to tumorigenesis and malignancy, as well as poor prognosis in several types of cancer (Birchmeier 2003; Hyner 2005; Yano 2003). It is reported that approximately 25% and 50% of gastric cancer (GC) patients express EGFR or cMet, respectively (Fuse 2016). Likewise, approximately 60% to 70% and 45% to 70% of esophageal cancer (EC) patients express EGFR or cMet, respectively (Hanawa 2006; Gibault 2005). The expression of EGFR or cMet has been implicated as a poor prognostic factor in GC (Aydin 2014; Gao 2013; Galizia 2007; Atmaca 2012; Fuse 2016) and EC (Wang 2007; Brand 2011; Ozawa 2015).
[0057] Despite numerous agents targeting EGFR (including anti-EGFR antibodies and EGFR tyrosine kinase inhibitors (TKIs)) having been used as a standard of care for many cancers, including colorectal cancer, non-small cell lung cancer (NSCLC), and head and neck cancer, no EGFR-directed therapy is available for gastric or ECs. Previous studies have failed to show efficacy of cetuximab and panitumumab, anti-EGFR antibodies, for the treatment of GC or gefitinib, EGFR tyrosine kinase inhibitor, in EC in non-biomarker selected population (Lordick 2013; Waddell 2013; Dutton 2014). A more recent study evaluating nimotuzumab, anti-EGFR antibody, in combination with irinotecan for GC patients with EGFR expression has also been shown to be unsuccessful (Satoh 2015). The clinical experience of cMet-targeted therapy is less extensive. The studies evaluating the efficacy of rilotumumab or onartuzumab, anti-cMet antibodies, in GC failed to show clinical benefit.
[0058] The present disclosure provides methods and compositions useful for treating gastric or esophageal cancer by targeting both EGFR and cMet.
Definitions
[0059] It is to be understood that the terminology used herein is for describing particular embodiments only and is not intended to be limiting. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.
[0060] Although any methods and materials similar or equivalent to those described herein may be used in the practice for testing of the present invention, exemplary materials and methods are described herein. In describing and claiming the present invention, the following terminology will be used.
[0061] When a list is presented, unless stated otherwise, it is to be understood that each individual element of that list, and every combination of that list, is a separate embodiment. For example, a list of embodiments presented as “A, B, or C” is to be interpreted as including the embodiments, “A,” “B,” “C,” “A or B,” “A or C,” “B or C,” or “A, B, or C.”
[0062] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a cell” includes a combination of two or more cells, and the like.
[0063] The conjunctive term “and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and/or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or.” [0064] The transitional terms “comprising,” “consisting essentially of,” and “consisting of’ are intended to connote their generally accepted meanings in the patent vernacular; that is, (i) “comprising,” which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; (ii) “consisting of’ excludes any element, step, or ingredient not specified in the claim; and (iii) “consisting essentially of’ limits the scope of a claim to the specified materials or steps “and
those that do not materially affect the basic and novel characteristic(s)” of the claimed invention. Embodiments described in terms of the phrase “comprising” (or its equivalents) also provide as embodiments those independently described in terms of “consisting of’ and “consisting essentially of.”
[0065] “Co-administration,” “administration with,” “administration in combination with,” “in combination with” or the like, encompass administration of the selected therapeutics or drugs to a single patient, and are intended to include treatment regimens in which the therapeutics or drugs are administered by the same or different route of administration or at the same or different time.
[0066] “Treat”, “treating” or “treatment” of a disease or disorder such as cancer refers to accomplishing one or more of the following: reducing the severity and/or duration of the disorder, inhibiting worsening of symptoms characteristic of the disorder being treated, limiting or preventing recurrence of the disorder in subjects that have previously had the disorder, or limiting or preventing recurrence of symptoms in subjects that were previously symptomatic for the disorder.
[0067] “Prevent”, “preventing”, “prevention”, or “prophylaxis” of a disease or disorder means preventing that a disorder occurs in subject.
[0068] “Responsive”, “responsiveness” or “likely to respond” refers to any kind of improvement or positive response, such as alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
[0069] “Therapeutically effective amount” refers to an amount effective, at doses and for periods of time necessary, to achieve a desired therapeutic result. A therapeutically effective amount may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic or combination of therapeutics that include, for example, improved well-being of the patient, decrease or shrinkage of the size of a tumor, arrested or slowed growth of a tumor, and/or absence of metastasis of cancer cells to other locations in the body.
[0070] “Refractory” refers to a disease that does not respond to a treatment. A refractory disease can be resistant to a treatment before or at the beginning of the treatment, or a refractory disease can become resistant during a treatment.
[0071] “Relapsed” refers to the return of a disease or the signs and symptoms of a disease after a period of improvement after prior treatment with a therapeutic.
[0072] “Subject” includes any human or nonhuman animal. “Nonhuman animal” includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc. The terms “subject” and “patient” are used interchangeably herein.
[0073] “About” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. Unless explicitly stated otherwise within the Examples or elsewhere in the Specification in the context of a particular assay, result or embodiment, “about” means within one standard deviation per the practice in the art, or a range of up to 5%, whichever is larger.
[0074] “Cancer” refers to an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize (spread) to other areas of a patient’s body.
[0075] “EGFR or c-Met or MET expressing cancer” refers to cancer that has detectable expression of EGFR or c-Met or has EGFR or c-Met mutation or amplification. EGFR or c-Met expression, amplification and mutation status can be detected using know methods, such as sequencing, fluorescent in situ hybridization, immunohistochemistry, flow cytometry or western blotting.
[0076] “Epidermal growth factor receptor” or “EGFR” refers to the human EGFR (also known as HER1 or ErbBl (Ullrich et al., Nature 309:418-425, 1984)) having the amino acid sequence shown in GenBank accession number NP_005219, as well as naturally occurring variants thereof.
[0077] “Hepatocyte growth factor receptor” or “c-Met” or “MET” as used herein refers to the human c-Met having the amino acid sequence shown in GenBank Accession No: NP_001120972 and natural variants thereof.
[0078] “Bispecific anti-EGFR/c-Met antibody” or “bispecific EGFR/c-Met antibody” refers to a bispecific antibody having a first domain that specifically binds EGFR and a second
domain that specifically binds c-Met. The domains specifically binding EGFR and c-Met are typically VH/VL pairs, and the bispecific anti-EGFR/c-Met antibody is monovalent in terms of binding to EGFR and c-Met.
[0079] “Specific binding” or “specifically binds” or “specifically binding” or “binds” refer to an antibody binding to an antigen or an epitope within the antigen with greater affinity than for other antigens. Typically, the antibody binds to the antigen or the epitope within the antigen with an equilibrium dissociation constant (KD) of about 5xl0-8 M or less, for example about IxlO-9 M or less, about IxlO 10 M or less, about IxlO 11 M or less, or about IxlO 12 M or less, typically with the KD that is at least one hundred-fold less than its KD for binding to a nonspecific antigen (e.g., BSA, casein). The dissociation constant may be measured using known protocols. Antibodies that bind to the antigen or the epitope within the antigen may, however, have cross-reactivity to other related antigens, for example to the same antigen from other species (homologs), such as human or monkey, for example Macaca fascicularis (cynomolgus, cyno) or Pan troglodytes (chimpanzee, chimp). While a monospecific antibody binds one antigen or one epitope, a bispecific antibody binds two distinct antigens or two distinct epitopes.
[0080] “Antibodies” is meant in a broad sense and includes immunoglobulin molecules including monoclonal antibodies including murine, human, humanized and chimeric monoclonal antibodies, antigen binding fragments, multispecific antibodies, such as bispecific, trispecific, tetraspecific etc., dimeric, tetrameric or multimeric antibodies, single chain antibodies, domain antibodies and any other modified configuration of the immunoglobulin molecule that comprises an antigen binding site of the required specificity. “Full length antibodies” are comprised of two heavy chains (HC) and two light chains (LC) inter-connected by disulfide bonds as well as multimers thereof (e.g., IgM). Each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (comprised of domains CHI, hinge, CH2 and CH3). Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL). The VH and the VL regions may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with framework regions (FR). Each VH and VL is composed of three CDRs and four FR segments, arranged from amino-to-carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
[0081] “Complementarity determining regions” (CDR) are antibody regions that bind an antigen. CDRs may be defined using various delineations such as Kabat (Wu et al. (1970) J Exp Med 132: 211-50) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), Chothia (Chothia et al. (1987) J Mol Biol 196: 901-17), IMGT (Lefranc et al. (2003) Dev Comp Immunol 27: 55-77) and AbM (Martin and Thornton (1996) J Bmol Biol 263: 800-15). The correspondence between the various delineations and variable region numbering are described (see e.g., Lefranc et al. (2003) Dev Comp Immunol 27: 55-77; Honegger and Pluckthun, (2001) J Mol Biol 309:657-70; International ImMunoGeneTics (IMGT) database; Web resources, http:// imgt_org). Available programs such as abY sis by UCL Business PLC may be used to delineate CDRs. The term “CDR”, “HCDR1”, “HCDR2”, “HCDR3”, “LCDR1”, “LCDR2” and “LCDR3” as used herein includes CDRs defined by any of the methods described supra, Kabat, Chothia, IMGT or AbM, unless otherwise explicitly stated in the specification
[0082] Immunoglobulins may be assigned to five major classes, IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence. IgA and IgG are further sub-classified as the isotypes IgAl, IgA2, IgGl, IgG2, IgG3 and IgG4. Antibody light chains of any vertebrate species may be assigned to one of two clearly distinct types, namely kappa (K) and lambda (X), based on the amino acid sequences of their constant domains.
[0083] “Antigen binding fragment” refers to a portion of an immunoglobulin molecule that binds an antigen. Antigen binding fragments may be synthetic, enzymatically obtainable or genetically engineered polypeptides and include the VH, the VL, the VH and the VL, Fab, F(ab')2, Fd and Fv fragments, domain antibodies (dAb) consisting of one VH domain or one VL domain, shark variable IgNAR domains, camelized VH domains, minimal recognition units consisting of the amino acid residues that mimic the CDRs of an antibody, such as FR3-CDR3- FR4 portions, the HCDR1, the HCDR2 and/or the HCDR3 and the LCDR1, the LCDR2 and/or the LCDR3. VH and VL domains may be linked together via a synthetic linker to form various types of single chain antibody designs where the VH/VL domains may pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate single chain antibody constructs, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody; described for example in Int. Patent Publ. Nos. W01998/44001, WO1988/01649, WO1994/13804 and W01992/01047.
[0084] “Monoclonal antibody” refers to an antibody obtained from a substantially homogenous population of antibody molecules, i.e., the individual antibodies comprising the population are identical except for possible well-known alterations such as removal of C- terminal lysine from the antibody heavy chain or post-translational modifications such as amino acid isomerization or deamidation, methionine oxidation or asparagine or glutamine deamidation. Monoclonal antibodies typically bind one antigenic epitope. A bispecific monoclonal antibody binds two distinct antigenic epitopes. Monoclonal antibodies may have heterogeneous glycosylation within the antibody population. Monoclonal antibody may be monospecific or multispecific such as bispecific, monovalent, bivalent or multivalent.
[0085] “Recombinant” refers to DNA, antibodies and other proteins that are prepared, expressed, created or isolated by recombinant means when segments from different sources are joined to produce recombinant DNA, antibodies or proteins.
[0086] “Bispecific” refers to an antibody that specifically binds two distinct antigens or two distinct epitopes within the same antigen. The bispecific antibody may have cross-reactivity to other related antigens, for example to the same antigen from other species (homologs), such as human or monkey, for example Macaca cynomolgus (cynomolgus, cyno) or Pan troglodytes, or may bind an epitope that is shared between two or more distinct antigens.
[0087] "Antagonist" or “inhibitor” refers to a molecule that, when bound to a cellular protein, suppresses at least one reaction or activity that is induced by a natural ligand of the protein. A molecule is an antagonist when the at least one reaction or activity is suppressed by at least about 20%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% more than the at least one reaction or activity suppressed in the absence of the antagonist (e.g., negative control), or when the suppression is statistically significant when compared to the suppression in the absence of the antagonist.
[0088] “PD-(L)1 axis inhibitor” refers to a molecule that inhibits PD-1 downstream signaling. PD-(L)1 axis inhibitor may be a molecule that binds PD-1, PD-L1 or PD-L2.
[0089] “Low fucose” or “low fucose content” as used in the application refers to antibodies with fucose content of about between 1 %- 15 %.
[0090] “Normal fucose” or “normal fucose content” as used herein refers to antibodies with fucose content of about over 50%, typically about over 80% or over 85%.
Methods of the disclosure
[0091] One aspect of the disclosure provides a method of treating gastric or esophageal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
[0092] In some embodiments, the disclosure provides a method of treating gastric cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
[0093] Gastric cancer referred to herein also includes esophagogastric junction (GEJ) cancer. In some embodiments, the gastric cancer is adenocarcinoma. In some embodiments, the gastric cancer is an advanced or metastatic cancer. For example, the gastric cancer may have metastasized to the esophagus, the small intestine, lymph nodes, organs, bones, or combinations thereof.
[0094] In some embodiments, the disclosure provides a method of treating esophageal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-EGFR/c-Met antibody.
[0095] In some embodiments, the esophageal cancer is adenocarcinoma. In some embodiments, the esophageal cancer is squamous cell carcinoma. In some embodiments, the esophageal cancer is an advanced or metastatic cancer. For example, the esophageal cancer may have metastasized to the lung, the small intestine, lymph nodes, organs, bones, or combinations thereof.
[0096] In some embodiments, the subject has received prior treatment. The prior treatment may include a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a combination thereof.
[0097] In some embodiments, the chemotherapy is a fluoropyrimidine-based chemotherapy, such as 5 -fluorouracil or capecitabine.
[0098] In some embodiments, the chemotherapy is a platinum-based chemotherapy.
Exemplary platinum-based chemotherapies include, but not limited to, cisplatin, oxaliplatin, carboplatin, or nedaplatin.
[0099] Additional examples of chemotherapy may include taxanes (e.g., paclitaxel, docetaxel), topoisomerase inhibitors (e.g., irinotecan, camptothecin), or a combination thereof.
[00100] In some embodiments, the targeted therapy is an anti-HER2 therapy or anti- VEGF/VEGFR therapy. Non-limiting examples of anti-HER2 therapy include trastuzumab. Nonlimiting examples of anti-VEGF/VEGFR therapy include bevacizumab or ramucirumab.
[00101] In some embodiments, the prior treatment comprises an immunotherapy such as checkpoint inhibitors. In some embodiments, the immunotherapy comprises a PD-(L)1 axis inhibitor, or a CTLA-4 inhibitor. Non-limiting examples of PD-(L) 1 axis inhibitors include atezolizumab, nivolumab, pembrolizumab, camrelizumab, and tislelizumab. Non-limiting examples of CTLA-4 inhibitors include ipilimumab.
[00102] In some embodiments, the prior treatment comprises an anti-VEGF/VEGFR therapy. Non-limiting examples of anti-VEGF/VEGFR therapy include bevacizumab and ramucirumab.
[00103] In some embodiments, the prior treatment comprises fluoropyrimidine and cisplatin. [00104] In some embodiments, the prior treatment comprises oxaliplatin and trastuzumab. [00105] In some embodiments, the prior treatment comprises ramucirumab and paclitaxel. [00106] In some embodiments, the prior treatment comprises fluorouracil and irinotecan.
[00107] In some embodiments, the prior treatment comprises fluorouracil and cisplatin.
[00108] In some embodiments, the subject is treatment naive.
[00109] In some embodiments, one or more cells of the gastric or esophageal cancer express EGFR and/or cMet. EGFR or c-Met expression can be detected using know methods, such as fluorescent in situ hybridization, immunohistochemistry (IHC), flow cytometry or western blotting.
[00110] In some embodiments, expression of EGFR and/or cMet is detected using immunohistochemistry (IHC), which measures EGFR and/or cMet protein levels on the cell surface. As a non-limiting example, a membrane staining intensity score (0, 1+, 2+, or 3+) may be determined for each cell in a fixed field. The tumor sample can be fixed in formalin paraffin embedded tissue (FFPE).
[00111] In some embodiments, the subject who receives the bispecific anti-EGFR/c-Met antibody has a staining intensity score of 1+ or above based on EGFR and/or cMet expression in a tumor sample obtained from the subject as determined by an IHC assay.
[00112] In some embodiments, the subject who receives the bispecific anti-EGFR/c-Met antibody has a staining intensity score of 2+ or above based on EGFR and/or cMet expression in a tumor sample obtained from the subject as determined by an IHC assay.
[00113] In some embodiments, the subject who receives the bispecific anti-EGFR/c-Met antibody has a staining intensity score of 3+ based on EGFR and/or cMet expression in a tumor sample obtained from the subject as determined by an IHC assay.
[00114] In some embodiments, an H score (or histo score) may be assigned to a tumor sample as a semiquantitative approach useful for analyses of immunohistochemical results (Hirsch FR et al., J Clin Oncol 21:3798-3807, 2003; John T et al., Oncogene 28:S14-S23, 2009, incorporated herein by reference in their entireties). In some embodiments, the H score may be based on a predominant staining intensity. In some embodiments, the H score may include the sum of individual H scores for each intensity level seen. As a non-limiting example, the percentage of cells at each staining intensity level may be calculated, and finally, an H score may be assigned using the following exemplary formula: [1 x (% cells 1+) + 2 x (% cells 2+) + 3 x (% cells 3+)]. The final calculated H score, ranging from 0 to 300, may give more relative weight to higher-intensity membrane staining in a given tumor sample. In some embodiments, the tumor sample may be considered either positive or a negative on the basis of a specific discriminatory threshold.
[00115] In some embodiments, a “combined H score” can be generated by adding an H score calculated from the analysis of one biomarker (e.g., EGFR expression) to an H score calculated from the analysis of a second biomarker (e.g., MET expression). Accordingly, the combined H score can have a range of 0 to 600.
Administration
[00116] The bispecific anti-EGFR/c-Met antibody may be administered in a pharmaceutically acceptable carrier. “Carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the antibody of the invention is administered. Such vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. For example, 0.4% saline and 0.3% glycine may be used to formulate the bispecific anti-EGFR/c-Met antibody. These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well-known sterilization techniques (e.g., filtration). For parenteral administration, the carrier may comprise sterile water and other excipients may be added to increase solubility or preservation. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.
For subcutaneous administration, a recombinant human hyaluronidase, such as rHuPH20 (CAS Registry No. 757971-58-7)) may be used. Suitable vehicles and formulations, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in e.g., Remington: The Science and Practice of Pharmacy, 21st Edition, Troy, D.B. ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing pp 691-1092, See especially pp. 958-989.
[00117] The mode of administration may be any suitable route that delivers the bispecific anti- EGFR-c-Met antibody to the host, such as parenteral administration, e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, intravaginal, rectal), using a formulation in a tablet, capsule, solution, powder, gel, particle; and contained in a syringe, an implanted device, osmotic pump, cartridge, micropump; or other means appreciated by the skilled artisan, as well known in the art. Site specific administration may be achieved by for example intratumoral, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intracardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravascular, intravesical, intralesional, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery.
[00118] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered intravenously. Exemplary intravenous formulations are disclosed in United States Patent Application Pub. No. US 2022/0064307 Al.
[00119] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally to the subject. The bispecific anti-EGFR/c-Met antibody may be administered subcutaneously or intradermally at a dose sufficient to achieve a therapeutic effect in the subject. Exemplary subcutaneous formulations are disclosed in United States Patent Application Pub. No. US 2022/0395573 Al.
[00120] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of between about 140 mg to about 1750 mg. In some embodiments, the bispecific anti- EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 2240 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of
between about 350 mg to about 1750 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 3340 mg.
[00121] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1010 mg, about 1020 mg, about 1030 mg, about 1040 mg, about 1050 mg, about 1060 mg, about 1070 mg, about 1080 mg, about 1090 mg, about 1100 mg, about 1110 mg, about 1120 mg, about 1130 mg, about 1140 mg, about 1150 mg, about 1160 mg, about 1170 mg, about 1180 mg, about 1190 mg, about 1200 mg, about 1210 mg, about 1220 mg, about 1230 mg, about 1240 mg, about 1250 mg, about 1260 mg, about 1270 mg, about 1280 mg, about 1290 mg, about 1300 mg, about 1310 mg, about 1320 mg, about 1330 mg, about 1340 mg, about 1350 mg, about 1360 mg, about 1370 mg, about 1380 mg, about 1390 mg, about 1400 mg, about 1410 mg, about 1420 mg, about 1430 mg, about 1440 mg, about 1450 mg, about 1460 mg, about 1470 mg, about 1480 mg, about 1490 mg, about 1500 mg, about 1510 mg, about 1520 mg, about 1530 mg, about 1540 mg, about 1550 mg, about 1560 mg, about 1570 mg, about 1580 mg, about 1590 mg, about 1600 mg, about 1610 mg,
1620 mg, about 1630 mg, about 1640 mg, about 1650 mg, about 1660 mg, about 1670 mg, about
1680 mg, about 1690 mg, about 1700 mg, about 1710 mg, about 1720 mg, about 1730 mg, about
1740 mg, about 1750 mg, about 1760 mg, about 1770 mg, about 1780 mg, about 1790 mg, about
1800 mg, about 1810 mg, about 1820 mg, about 1830 mg, about 1840 mg, about 1850 mg, about
1860 mg, about 1870 mg, about 1880 mg, 1890 mg, about 1900 mg, about 1910 mg, about 1920
mg, about 1930 mg, about 1940 mg, about 1950 mg, about 1960 mg, about 1970 mg, about 1980 mg, about 1990 mg, about 2000 mg, about 2010 mg, about 2020 mg, about 2030 mg, about 2040 mg, about 2050 mg, about 2060 mg, about 2070 mg, about 2080 mg, about 2090 mg, about 2100 mg, about 2110 mg, about 2120 mg, about 2130 mg, about 2140 mg, about 2150 mg, about 2160 mg, about 2170 mg about 2180 mg, about 2190 mg, about 2200 mg, about 2210 mg, about 2220 mg, about 2230 mg, about 2240 mg, about 2250 mg, about 2300 mg, about 2400 mg, about 2500 mg, about 2600 mg, about 2700 mg, about 2800 mg, about 2900 mg, about 3000 mg, about 3100 mg, about 3200 mg, about 3300 mg, about 3360 mg, or about 3400 mg.
[00122] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 350 mg, about 700 mg, about 1050 mg, about 1400 mg, about 1575 mg, about 1600 mg, about 1750 mg, about 2100 mg, about 2240 mg, about 2400 mg, or about 3360 mg,. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 350 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 700 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 750 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 800 mg. In some embodiments, the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 850 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 900 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 950 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1000 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1050 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1100 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1150 mg. In some embodiments, the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 1200 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1250 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1300 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1350 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 1575 mg. In some embodiments, the bispecific anti-EGFR/c-Met
antibody is administered at a dose of about 1600 mg. In some embodiments, the bispecific anti- EGFR/c-Met antibody is administered at a dose of about 1750 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 2100 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 2240 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 2400 mg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 3360 mg.
[00123] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 1050 mg if the subject has a body weight of less than 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 1050 mg even if the subject has a body weight of greater than or equal to 80 kg.
[00124] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg if the subject has a body weight of greater than or equal to 80 kg.
[00125] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1050 mg once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1400 mg once a week. In some embodiments, the bispecific anti-EGFR/c- Met antibody is administered about 1600 mg once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1750 mg once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 2100 mg once a week.
[00126] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1050 mg once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1400 mg once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1600 mg once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 1750 mg once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered about 2100 mg once in two weeks.
[00127] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 1575 mg if the subject has a body weight of less than 80 kg. In some
embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg if the subject has a body weight of greater than or equal to 80 kg.
[00128] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 1600 mg if the subject has a body weight of less than 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg if the subject has a body weight of greater than or equal to 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered weekly for the first 4 weeks, and once every 2 weeks thereafter.
[00129] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered is administered at a dose of 2400 mg if the subject has a body weight of less than 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg if the subject has a body weight of greater than or equal to 80 kg. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered weekly for the first 3 weeks, and once every 3 weeks thereafter.
[00130] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered twice a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once a week. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once in two weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once in three weeks. In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once in four weeks.
[00131] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks.
[00132] In some embodiments, the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter.
[00133] In some embodiments, the first dose of the bispecific anti-EGFR/c-Met antibody is administered in two days. As a non-limiting example, the first dose of the bispecific anti- EGFR/c-Met antibody may be split to two days with Day 1 (350 mg) and Day 2 (700 mg if body weight is <80 kg or 1,050 mg if body weight is >80 kg).
[00134] In some embodiments, the method further comprises administering at least one additional therapeutic to the subject. In some embodiments, the additional therapeutic is a
glucocorticosteroid, antihistamine, antipyretic, H2-antagonist, antiemetic, opiate, or any combination thereof.
[00135] In some embodiments, the at least one additional therapeutic is administered prior to the one or more treatment doses.
[00136] In some embodiments, the glucocorticosteroid is dexamethasone, beclomethasone, betamethasone, budesonide, cortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone. In some embodiments, the glucocorticosteroid is dexamethasone or methylprednisolone. For example, the glucocorticosteroid is dexamethasone (10 mg) or methylprednisolone (40 mg).
[00137] The glucocorticosteroid (e.g., dexamethasone, methylprednisolone) may be administered intravenously (IV) approximately 45-60 minutes prior to the administration of the bispecific anti-EGFR/c-Met antibody. Alternatively, the glucocorticosteroid (e.g., dexamethasone, methylprednisolone) may be administered orally 60-90 min prior to the administration of the bispecific anti-EGFR/c-Met antibody.
[00138] In some embodiments, the antihistamine is diphenhydramine, brompheniramine, chlorpheniramine, clemastine, cyproheptadine, dexchlorpheniramine dimenhydrinate, doxylamine, hydroxyzine, phenindamine, azelastine, loratadine, cetirizine, desloratadine, or fexofenadine. In some embodiments, the antihistamine is diphenhydramine. For example, the antihistamine may be diphenhydramine (about 25-50 mg) or equivalent.
[00139] In some embodiments, the antihistamine medication is administered orally approximately 30-60 prior to administration of the bispecific anti-EGFR/c-Met antibody. In some embodiments, the antihistamine medication is administered intravenously approximately 15 to 30 minutes prior to administration of the bispecific anti-EGFR/c-Met antibody.
[00140] In some embodiments, the antipyretic is acetaminophen, ibuprofen, naproxen, ketoprofen, and nimesulide, aspirin, choline salicylate, magnesium salicylate, sodium salicylate, or phenazone (antipyrine). In some embodiments, the antipyretic is acetaminophen. For example, the antipyretic may be acetaminophen (about 650 mg to 1 ,000 mg) or equivalent.
[00141] In some embodiments, the antipyretic medication is administered intravenously approximately 15 to 30 min or orally approximately 30-60 min prior to administration of the bispecific anti-EGFR/c-Met antibody.
[00142] In some embodiments, the ^-antagonist is ranitidine, cimetidine, famotidine, or nizatidine. In some embodiments, the ^-antagonist is ranitidine. For example, the ^-antagonist may be ranitidine (about 50 mg) or equivalent.
[00143] In some embodiments, the H2-antagonist medication is administered intravenously approximately 15-30 minutes prior to administration of the bispecific anti-EGFR/c-Met antibody or orally approximately 60 minutes prior to administration of the bispecific anti-EGFR/c-Met antibody.
[00144] In some embodiments, the antiemetic is ondansetron, meclizine, dimenhydrinate, prochlorperazine, promethazine, vitamin B6, droperidol, granisetron, metoclopramide, aprepitant, dolasetron, palonosetron, rolapitant. In some embodiments, the antiemetic is ondansetron. For example, the antiemetic may be ondansetron (about 16 mg) or equivalent. [00145] In some embodiments, the antiemetic medication is administered intravenously approximately 15 to 30 minutes prior to administration of the bispecific anti-EGFR/c-Met antibody or orally about 15 to 30 minutes prior to administration of the bispecific anti-EGFR/c- Met antibody.
[00146] In some embodiments, the at least one additional therapeutic described herein is administered after the one or more treatment doses. The at least one additional therapeutic may be administered up to 48 hours after the one or more treatment doses if clinically indicated. [00147] As a non-limiting example, a glucocorticosteroid (e.g., dexamethasone (10 mg)), an antihistamine (e.g., diphenhydramine (25-50 mg)), an antipyretic (e.g., acetaminophen (650- 1,000 mg)), and/or an opiate (e.g., meperidine (25-100 mg)) may be administered intravenously or orally after the administration of one or more treatment doses of the bispecific anti-EGFR/c- Met antibody if needed. Additionally, an antiemetic medication may be administered intravenously (e.g., ondansetron (8-16 mg)) or orally (e.g., ondansetron (8 mg)) to the subject after the one or more treatment doses if needed.
Generation of bispecific anti-EGFR/c-Met antibodies
[00148] An exemplary bispecific anti-EGFR/c-Met antibody that can be used in the methods of the disclosures is amivantamab. Amivantamab is an IgGl anti-EGFR/c-Met bispecific antibody described in U.S. Pat. No. 9,593,164, which is incorporated herein by reference in its entirety.
[00149] Amivantamab is a low fucose, fully human immunoglobulin G1 (IgGl)-based bispecific antibody directed against the EGFR and MET receptors, shows preclinical activity against tumors with overexpressed wild type EGFR and activation of the MET pathway. Unlike EGFR TKIs, which bind to the intracellular portion of the EGFR, amivantamab targets the extracellular domain of both EGFR and MET. Amivantamab may have at least 3 potential mechanisms of action, including 1) inhibition of ligand-dependent signaling, 2) downregulation of EGFR and MET expression levels, and 3) initiation of antibody-dependent cellular cytotoxicity (ADCC). Amivantamab is produced with low levels of fucosylation, which translates to an enhanced level of ADCC activity. The human Fcyllla receptor, critical for ADCC, binds low fucose antibodies more tightly and consequently mediates more potent and effective ADCC killing of target cancer cells (Satoh, 2006). It is hypothesized that by targeting the extracellular domain of EGFR and MET, amivantamab can inhibit receptors that display primary resistance to EGFR TKIs (Exon 20 insertion) or have acquired either EGFR resistance mutations (T790M or C797S) or secondary activation of the MET pathway (MET amplification).
[00150] Amivantamab is characterized by following amino acid sequences: EGFR binding arm
>SEQ ID NO: 1 (HCDR1, EGFR binding arm) TYGMH
>SEQ ID NO: 2 (HCDR2, EGFR binding arm) VIWDDGSYKYYGDSVKG
>SEQ ID NO: 3 (HCDR3, EGFR binding arm) DGITMVRGVMKDYFDY
>SEQ ID NO: 4 (LCDR1, EGFR binding arm) RASQDISSALV
>SEQ ID NO: 5 (LCDR2, EGFR binding arm) DASSLES
>SEQ ID NO: 6 (LCDR3, EGFR binding arm)
QQFNSYPLT
>SEQ ID NO: 7 (HCDR1, c-Met binding arm)
SYGIS
>SEQ ID NO: 8 (HCDR2, c-Met binding arm)
WISAYNGYTNYAQKLQG
>SEQ ID NO:9 (HCDR3, c-Met binding arm)
DLRGTNYFDY
>SEQ ID NO: 10 (LCDR1, c-Met binding arm)
RASQGISNWLA
>SEQ ID NO: 11 (LCDR2, c-Met binding arm)
AASSLLS
>SEQ ID NO: 12 (LCDR3, c-Met binding arm)
QQANSFPIT
>SEQ ID NO: 13 (VH, EGFR binding arm)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSY KYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDY WGQGTLVTVSS
>SEQ ID NO: 14 (VL, EGFR binding arm)
AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSR FSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK
>SEQ ID NO: 15 (VH, c-Met binding arm)
QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGY
TNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTL VTVSS
>SEQ ID NO: 16 (VL, c-Met binding arm)
DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK
>SEQ ID NO: 17 HC1
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSY
KYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDY
WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFLLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>SEQ ID NO: 18 LC1
AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSR
FSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>SEQ ID NO: 19 HC2
QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGY
TNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTL VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>SEQ ID NO: 20 LC2
DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIKRTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[00151] In some embodiments, the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6; and the second domain comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
[00152] In some embodiments, the first domain that specifically binds EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14; and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
[00153] In some embodiments, the bispecific anti-EGFR/c-Met antibody is an IgGl isotype. [00154] In some embodiments, the bispecific anti-EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
[00155] In one embodiment, the bispecific anti-EGFR/c-Met antibody comprises one or more Fc silencing mutations.
[00156] In one embodiment, the one or more Fc silencing mutations decrease affinity to Fey receptors.
[00157] In one embodiment, the one or more Fc silencing mutations comprise V234A/G237A/P238S/H268A/V309L/A330S/P331S.
[00158] In one embodiment, the bispecific anti-EGFR/c-Met antibody comprises a biantennary glycan structure with a fucose content between about 1% to about 15%. Antibodies with reduced fucose content can be made using different methods reported to lead to the successful expression of relatively high defucosylated antibodies bearing the biantennary complex-type of Fc oligosaccharides such as control of culture osmolality (Konno et al., Cytotechnology 64(: 249-65, 2012), application of a variant CHO line Lecl3 as the host cell line (Shields et al., J Biol Chem 277:26733-26740, 2002), application of a variant CHO line EB66 as the host cell line (Olivier et al., MAbs ;2(4), 2010; Epub ahead of print; PMID:20562582), application of a rat hybridoma cell line YB2/0 as the host cell line (Shinkawa et al., J Biol Chem 278:3466-3473, 2003), introduction of small interfering RNA specifically against the > 1,6-fucosyltrasferase ( FUT8) gene (Mori et al., Biotechnol Bioeng88:901-908, 2004), or coexpression of P-l,4-N- acetylglucosaminyltransferase III and Golgi a-mannosidase II or a potent alpha-mannosidase I inhibitor, kifunensine (Ferrara et al., J Biol Chem281:5032-5036, 2006, Ferrara et al., Biotechnol Bioeng 93:851-861, 2006; Xhou et al., Biotechnol Bioeng 99:652-65, 2008). In general, lowering fucose content in the glycan of the antibodies potentiates antibody-meidated cellular cytotoxicity (ADCC).
[00159] Other bispecific anti-EGFR/c-Met antibodies may also be used in the methods of the disclosure as long as they demonstrate similar characteristics when compared to amivantamab as described in U.S. Pat. No. 9,593,164. Bispecific anti-EGFR/c-Met antibodies that may be used in the methods of the disclosure may also be generated by combining EGFR binding VH/VL domains and c-Met binding VH/VL domains and testing the resulting bispecific antibodies for their characteristics as described in U.S. Pat. No. 9,593,164.
[00160] Bispecific anti-EGFR/c-Met antibodies used in the methods of the disclosure may be generated for example using Fab arm exchange (or half molecule exchange) between two monospecific bivalent antibodies by introducing substitutions at the heavy chain CH3 interface in each half molecule to favor heterodimer formation of two antibody half molecules having distinct specificity either in vitro in cell-free environment or using co-expression. The Fab arm exchange reaction is the result of a disulfide -bond isomerization reaction and dissociationassociation of CH3 domains. The heavy chain disulfide bonds in the hinge regions of the
parental monospecific antibodies are reduced. The resulting free cysteines of one of the parental monospecific antibodies form an inter heavy-chain disulfide bond with cysteine residues of a second parental monospecific antibody molecule and simultaneously CH3 domains of the parental antibodies release and reform by dissociation-association. The CH3 domains of the Fab arms may be engineered to favor heterodimerization over homodimerization. The resulting product is a bispecific antibody having two Fab arms or half molecules which each bind a distinct epitope, i.e. an epitope on EGFR and an epitope on c-Met. For example, the bispecific antibodies of the invention may be generated using the technology described in Int.Pat. Publ. No. WO2011/131746. Mutations F405L in one heavy chain and K409R in the other heavy chain may be used in case of IgGl antibodies. For IgG2 antibodies, a wild-type IgG2 and a IgG2 antibody with F405L and R409K substitutions may be used. For IgG4 antibodies, a wild-type IgG4 and a IgG4 antibody with F405L and R409K substitutions may be used. To generate bispecific antibodies, first monospecific bivalent antibody and the second monospecific bivalent antibody are engineered to have the aforementioned mutation in the Fc region, the antibodies are incubated together under reducing conditions sufficient to allow the cysteines in the hinge region to undergo disulfide bond isomerization; thereby generating the bispecific antibody by Fab arm exchange. The incubation conditions may optimally be restored to non-reducing. Exemplary reducing agents that may be used are 2- mercaptoethylamine (2-MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2-carboxyethyl)phosphine (TCEP), L-cysteine and betamercaptoethanol. For example, incubation for at least 90 min at a temperature of at least 20°C in the presence of at least 25 mM 2-MEA or in the presence of at least 0.5 mM dithiothreitol at a pH of from 5-8, for example at pH of 7.0 or at pH of 7.4 may be used.
[00161] Bispecific anti-EGFR/c-Met antibodies used in the methods of the disclosure may also be generated using designs such as the knob-in-hole or knobs-into-holes (Genentech), CrossMAbs (Roche) and the electrostatically-matched (Chugai, Amgen, NovoNordisk, Oncomed), the LUZ-Y (Genentech), the Strand Exchange Engineered Domain body (SEEDbody)(EMD Serono), and the Biclonic (Merus).
[00162] In the “knob-in-hole” strategy (see, e.g., Inti. Publ. No. WO 2006/028936) select amino acids forming the interface of the CH3 domains in human IgG can be mutated at positions affecting CH3 domain interactions to promote heterodimer formation. An amino acid with a small side chain (hole) is introduced into a heavy chain of an antibody specifically binding a first
antigen and an amino acid with a large side chain (knob) is introduced into a heavy chain of an antibody specifically binding a second antigen. After co-expression of the two antibodies, a heterodimer is formed as a result of the preferential interaction of the heavy chain with a “hole” with the heavy chain with a “knob”. Exemplary CH3 substitution pairs forming a knob and a hole are (expressed as modified position in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): T366Y/F405A, T366W/F405W, F405W/Y407A, T394W/Y407T, T394S/Y407A, T366W/T394S, F405W/T394S and T366W/T366S_E368A_Y407V.
[00163] CrossMAb technology, in addition to utilizing the “knob-in-hole” strategy to promoter Fab arm exchange utilizes CH1/CE domain swaps in one half arm to ensure correct light chain pairing of the resulting bispecific antibody (see e.g., U.S. Patent No. 8,242,247).
[00164] Other cross-over strategies may be used to generate full length bispecific antibodies of the invention by exchanging variable or constant, or both domains between the heavy chain and the light chain or within the heavy chain in the bispecific antibodies, either in one or both arms. These exchanges include for example VH-CH1 with VE-CE, VH with VE, CH3 with CL and CH3 with CHI as described in Int. Patent Publ. Nos. W02009/080254, W02009/080251, W02009/018386 and W02009/080252.
[00165] Other strategies such as promoting heavy chain heterodimerization using electrostatic interactions by substituting positively charged residues at one CH3 surface and negatively charged residues at a second CH3 surface may be used, as described in US Patent Publ. No. US2010/0015133; US Patent Publ. No. US 2009/0182127; US Patent Publ. No. US2010/028637 or US Patent Publ. No. US2011/0123532. In other strategies, heterodimerization may be promoted by following substitutions (expressed as modified positions in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): L351 Y_F405A_Y407V/T394W, T366I_K392M_T394W/F405A_Y407V, T366L_K392M_T394W/F405A_Y407V, L351 Y_Y407A/T366A_K409F, L351Y_Y407A/T366V_K409F, Y407A/T366A_K409F, or
T350V_L351Y_F405A_Y407V/T350V_T366L_K392L_T394W as described in U.S. Patent Publ. No. US2012/0149876 or U.S. Patent Publ. No. US2013/0195849.
[00166] SEEDbody technology may be utilized to generate bispecific antibodies of the invention. SEEDbodies have, in their constant domains, select IgG residues substituted with IgA residues to promote heterodimerization as described in U.S. Patent No. US20070287170.
[00167] Mutations are typically made at the DNA level to a molecule such as the constant domain of the antibody using standard methods.
Exemplary Embodiments
[00168] 1. A method of treating gastric cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.
[00169] 2. The method of embodiment 1 , wherein the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6, and wherein the second domain that binds c-Met comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
[00170] 3. The method of embodiment 2, wherein the first domain that specifically binds
EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
[00171] 4. The method of embodiment 2 or 3, wherein the bispecific anti-EGFR/c-Met antibody is an IgGl isotype.
[00172] 5. The method of any one of embodiments 1 -4, wherein the bispecific anti-EGFR/c- Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
[00173] 6. The method of any one of embodiments 1-5, wherein the bispecific anti-EGFR/c- Met antibody comprises a biantennary glycan structure with a fucose content of about between 1% to about 15%.
[00174] 7. The method of any one of embodiments 1 -6, wherein the bispecific anti-EGFR/c- Met antibody is administered intravenously or subcutaneously to the subject.
[00175] 8. The method of embodiment 7, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 2000 mg.
[00176] 9. The method of embodiment 8, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 350 mg, 700 mg, about 750 mg, about 800 mg, about 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, 2000 mg 2100 mg, 2200 mg, 2240 mg, 2300 mg, 2400 mg, 2500 mg, 2600 mg, 2700 mg, 2800 mg, 2900 mg, 3000 mg, 3100 mg, 3200 mg, 3300 mg, 3360 mg, or 3400 mg.
[00177] 10. The method of embodiment 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1050 mg.
[00178] 11. The method of embodiment 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg.
[00179] 12. The method of embodiment 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1600 mg.
[00180] 13. The method of embodiment 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1750 mg.
[00181] 14. The method of embodiment 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg.
[00182] 15. The method of embodiment 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg.
[00183] 16. The method of embodiment 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2400 mg.
[00184] 17. The method of embodiment 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg.
[00185] 18. The method of any one of the embodiments 10-15 wherein the bispecific anti- EGFR/c-Met antibody is administered weekly for the first 4 weeks, and once every 2 weeks thereafter.
[00186] 19. The method of embodiments 16 or 17, wherein the bispecific anti-EGFR/c-Met antibody is administered weekly for the first 3 weeks, and once every 3 weeks thereafter.
[00187] 20. The method of any one of the embodiments 10-19, wherein the bispecific anti- EGFR/c-Met antibody is administered subcutaneously.
[00188] 21. The method of embodiment 18, wherein the bispecific anti-EGFR/c-Met antibody is administered intravenously.
[00189] 22. The method of any one of embodiments 1-6, wherein the bispecific anti-EGFR/c- Met antibody is administered subcutaneously or intradermally to the subject.
[00190] 23. The method of embodiment 22, wherein the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally at a dose sufficient to achieve a therapeutic effect in the subject.
[00191] 24. The method of any one of embodiments 1-23, wherein the bispecific anti- EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks.
[00192] 25. The method of embodiment 24, wherein the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter.
[00193] 26. The method of embodiment 25, wherein the first dose of the bispecific anti- EGFR/c-Met antibody is administered over two days.
[00194] 27. The method of any one of embodiments 1-26, wherein one or more cells of the gastric cancer express EGFR and/or cMet.
[00195] 28. The method of any one of embodiments 1-27, wherein the subject has received a prior treatment.
[00196] 29. The method of embodiment 28, wherein the prior treatment comprises a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a combination thereof.
[00197] 30. The method of embodiment 29, wherein the chemotherapy comprises a fluoropyrimidine -based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof.
[00198] 31. The method of embodiment 30, wherein the fluoropyrimidine is 5 -fluorouracil or capecitabine.
[00199] 32. The method of embodiment 30, wherein the platinum-based chemotherapy is cisplatin, oxaliplatin, carboplatin, or nedaplatin.
[00200] 33. The method of embodiment 29, wherein the targeted therapy comprises an anti- HER2 therapy or anti-VEGF/VEGFR therapy.
[00201] 34. The method of embodiment 33, wherein the anti-HER2 therapy comprises trastuzumab.
[00202] 35. The method of embodiment 34, wherein the anti-VEGF/VEGFR therapy comprises bevacizumab or ramucirumab.
[00203] 36. The method of any one of embodiments 1-27, wherein the subject is treatment naive.
[00204] 37. The method of any one of embodiments 1-36, wherein the method further comprises administering at least one additional therapeutic to the subject.
[00205] 38. The method of embodiment 37, wherein the additional therapeutic comprises a glucocorticosteroid, antihistamine, antipyretic, H2-antagonist, antiemetic, opiate, or any combination thereof.
[00206] 39. The method of any one of embodiments 1-38, wherein the gastric cancer is an advanced or metastatic cancer.
[00207] 40. The method of any one of embodiments 1-39, wherein the subject is human.
[00208] 41. A method of treating esophageal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.
[00209] 42. The method of embodiment 41, wherein the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6, and wherein the second domain that binds c-Met comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID
NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
[00210] 43. The method of embodiment 42, wherein the first domain that specifically binds EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
[00211] 44. The method of embodiment 42 or 43, wherein the bispecific anti-EGFR/c-Met antibody is an IgGl isotype.
[00212] 45. The method of any one of embodiments 41-44, wherein the bispecific anti- EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20.
[00213] 46. The method of any one of embodiments 41-45, wherein the bispecific anti- EGFR/c-Met antibody comprises a biantennary glycan structure with a fucose content of about between 1% to about 15%.
[00214] 47. The method of any one of embodiments 41-46, wherein the bispecific anti- EGFR/c-Met antibody is administered intravenously or subcutanously to the subject.
[00215] 48. The method of embodiment 47, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 2000 mg.
[00216] 49. The method of embodiment 48, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 350 mg, 700 mg, about 750 mg, about 800 mg, about 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, 2000 mg, or 2100 mg, 2200 mg, 2240 mg, 2300 mg, 2400 mg, 2500 mg, 2600 mg, 2700 mg, 2800 mg, 2900 mg, 3000 mg, 3100 mg, 3200 mg, 3300 mg, 3360 mg, or 3400 mg.
[00217] 50. The method of embodiment 49, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1050 mg.
[00218] 51. The method of embodiment 49, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg.
[00219] 52. The method of embodiment 49, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1600 mg.
[00220] 53. The method of embodiment 49, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1750 mg.
[00221] 54. The method of embodiment 49, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg.
[00222] 55. The method of embodiment 49, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg.
[00223] 56. The method of embodiment 49, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2400 mg.
[00224] 57. The method of embodiment 49, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg.
[00225] 58. The method of any one of the embodiments 50-55 wherein the bispecific anti- EGFR/c-Met antibody is administered weekly for the first 4 weeks, and once every 2 weeks thereafter.
[00226] 59. The method of embodiments 56 or 57, wherein the bispecific anti-EGFR/c-Met antibody is administered weekly for the first 3 weeks, and once every 3 weeks thereafter.
[00227] 60. The method of embodiment 58, wherein the bispecific anti-EGFR/c-Met antibody is administered intravenously.
[00228] 61. The method of embodiment 59, wherein the bispecific anti-EGFR/c-Met antibody is administered subcutaneously.
[00229] 62. The method of any one of the embodiments 50-59 wherein the bispecific anti- EGFR/c-Met antibody is administered subcutaneously.
[00230] 63. The method of any one of embodiments 41-57, wherein the bispecific anti- EGFR/c-Met antibody is administered subcutaneously or intradermally to the subject.
[00231] 64. The method of embodiment 63, wherein the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally at a dose sufficient to achieve a therapeutic effect in the subject.
[00232] 65. The method of any one of embodiments 41-64, wherein the bispecific anti- EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks.
[00233] 66. The method of embodiment 65, wherein the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter.
[00234] 67. The method of embodiment 66, wherein the first dose of the bispecific anti- EGFR/c-Met antibody is administered over two days.
[00235] 68. The method of any one of embodiments 41-67, wherein one or more cells of the esophageal cancer express EGFR and/or cMet.
[00236] 69. The method of any one of embodiments 41-68, wherein the subject has received a prior treatment.
[00237] 70. The method of embodiment 69, wherein the prior treatment comprises a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a combination thereof.
[00238] 71. The method of embodiment 70, wherein the chemotherapy comprises a fluoropyrimidine -based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof.
[00239] 72. The method of embodiment 71, wherein the fluoropyrimidine is 5 -fluorouracil or capecitabine.
[00240] 73. The method of embodiment 71, wherein the platinum-based chemotherapy is cisplatin, oxaliplatin, carboplatin, or nedaplatin.
[00241] 74. The method of embodiment 70, wherein the targeted therapy comprises an anti- HER2 therapy or anti-VEGF/VEGFR therapy.
[00242] 75. The method of embodiment 74, wherein the anti-HER2 therapy comprises trastuzumab.
[00243] 76. The method of embodiment 74, wherein the anti-VEGF/VEGFR therapy comprises bevacizumab or ramucirumab.
[00244] 77. The method of any one of embodiments 41-68, wherein the subject is treatment naive.
[00245] 78. The method of any one of embodiments 41-77, wherein the method further comprises administering at least one additional therapeutic to the subject.
[00246] 79. The method of embodiment 78, wherein the additional therapeutic is a glucocorticosteroid, antihistamine, antipyretic, H2-antagonist, antiemetic, opiate, or any combination thereof.
[00247] 80. The method of any one of embodiments 41-79, wherein the esophageal cancer is an advanced or metastatic cancer.
[00248] 81. The method of any one of embodiments 41-80, wherein the subject is human.
EXAMPLES
[00249] The following examples are provided to further describe some of the embodiments disclosed herein. The examples are intended to illustrate, not to limit, the disclosed embodiments.
Example 1. A Phase 2, Open-label Study of Amivantamab in Subjects with Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Study Rationale
[00250] Gastric cancers (GCs) and esophageal cancer (ECs) have been known to express EGFR and cMet and the expression of these proteins have corelated with poor prognosis. Although many agents targeting EGFR are part of standard of care for many tumor types, no anti-EGFR or anti-cMet therapy has been approved in GC or EC. As a bispecific duobody capable of engaging the extracellular domains of both EGFR and cMet receptors, amivantamab has a unique mechanism of action that suggests it has the potential to control EGFR-expressed and/or cMet-expressed GC and EC patients. Amivantamab has demonstrated in vitro and in vivo pre-clinical activities against tumors with the EGFR or cMet amplified GC and EC models (Vijayaraghavan 2020). Furthermore, clinical experience of amivantamab in NSCLC has shown clinical benefit against broad-spectrum of EGFR and cMet aberrations, including EGFR protein overexpression and cMet amplifications.
[00251 ] This study aims to evaluate the clinical activity of amivantamab as a monotherapy in GC (including GEJ cancer) and EC patients who had received at least 2 prior lines (GC/GEJ participants) or 1 prior line (EC participants) of standard therapy. The Phase 2a cohorts aim to initially investigate the anti-tumor activity of amivantamab in participants with documented expression of either EGFR, cMet, or both as evaluated by immunohistochemistry (IHC). Approximately 30 participants with any expression level of EGFR, cMet, or both proteins are enrolled in each of the Phase 2a cohort. However, based on the prior experiences investigating anti-EGFR and anti-cMet antibodies in gastroesophageal cancers, at least 20 participants expressing IHC 2+ or higher (defined as participants expressing EGFR IHC 2+ or above
and/or cMet IHC 2+ or above) are enrolled. Additional enrollment in Phase 2a cohorts may be allowed to achieve this minimal enrollment. Moreover, at least 10 participants expressing any level of cMet protein are enrolled in each of Phase 2a cohort to better characterize the contribution of cMet in amivantamab activity. If activity is demonstrated in the Phase 2a cohorts, Phase 2a extension cohorts investigating participants without expression of EGFRand cMet, may open for enrollment. The Phase 2b cohorts investigate the clinical activity of amivantamab in selected patient population based on the Phase 2a data.
Abbreviations : AE=adverse event; C=Cycle ; ctDNA=circulating tumor DNA; CT =computerized tomography; cMet= tyrosine-protein kinase mesenchymal-epithelial transition; D=Day ;
ECG=electrocardiogram; ECOG=Eastem Cooperative Oncology Group; EGFR= epidermal growth factor receptor; EoT=end-of-treatment; FU=follow-up; HBV=hepatitis B virus; HCV=hepatitis C virus;
HIV=human immunodeficiency virus; h=hour; ICF=informed consent form; IHC=Immunohistochemistry;
IV=intravenous; MRI=magnetic resonance imaging; Q12W=every 12 weeks; wk(s)=week(s)
Benefit-risk Assessment
Risks for Study Participation
[00252] The safety and tolerability of amivantamab monotherapy was shown in the Phase 1 Study 61186372EDI1001 in NSCLC patients. Amivantamab was generally well tolerated without any occurrence of dose limiting toxicities (DLTs). However, given that the available
clinical data are limited to NSCLC participants, unforeseen safety risks associated with the study treatments are possible in GC or EC participants. This study protocol includes the following elements to mitigate risks for study participants:
• Participants are monitored closely for safety throughout the study (refer to Safety Assessments Section), per the scheduled assessments outlined in the Schedule of Activities (Table 1).
• Dose modification guidance is provided to manage toxicities that occur during the study (refer to Dose Delay Guidance Section and Dose Modification Guidance Section), including specific guidance for infusion-related reactions (IRRs), rash, interstitial lung disease (ILD), liver test abnormalities, or paronychia.
[00253] Amivantamab is generally safe and well tolerated based on the data mentioned above.
Benefits for Study Participation
[00254] Although many agents targeting EGFR have been approved and are part of standard of care for many tumor types, no anti-EGFR or anti-cMet therapy has been approved in GC or EC. Amivantamab has demonstrated significant activity as monotherapy for the treatment of NSCEC, receiving Breakthrough Therapy Designation by the US FDA and China Center for Drug Evaluation, based on an overall response rate of 41% in subjects with EGFR Exon20ins disease, after prior treatment with platinum-based chemotherapy. Consistent with the unique mechanism of action of amivantamab, activity was observed in subjects with diverse EGFR mutations, as well as in subjects with amplification of MET and overexpressed EGFR.
[00255] It is anticipated that using this therapeutic targeted approach with amivantamab as a single agent in either advanced GC (including GEJ cancer) or EC participants may provide benefit to these participants.
Benefit-risk Assessment for Study Participation
[00256] Considering the measures taken to minimize risk to participants of this study (refer to Risks for Study Participation Section), the potential risks of amivantamab are justified by the anticipated benefits that may be afforded to participants with advanced GC or EC (refer to Benefits for Study Participation Section).
Table 2. Objectives and Endpoints
Hypothesis
[00257] Amivantamab is expected to exhibit anti-tumor activity in participants with GC or EC expressing any level of EGFR, cMET, or both proteins.
Study Design
Overall Design
[00258] This is an open-label, multicenter, multi-arm Phase 2 interventional study in participants with previously treated advanced or unresectable GC or EC who are 20 years or older (or the legal age of consent in the jurisdiction in which the study is taking place). Japanese participants with gastric/GEJ or EC who express varying degrees of EGFR, cMet, or both as determined by IHC locally or centrally are enrolled in the GC cohort or EC cohort. If activity is demonstrated in the Phase 2a cohorts, Phase 2a extension cohorts investigating participants
without expression of EGFR and cMet, may open for enrollment. If activity is observed within the Phase 2a cohorts, the corresponding Phase 2b GC or EC expansion cohorts may be initiated to evaluate the antitumor activity of amivantamab in selected GC and EC participants based upon the prospective assessment of IHC during Phase 2a (Figure 1).
[00259] A maximum of approximately 282 participants are enrolled in the combined Phase 2a and Phase 2b populations, in the event the efficacy observed in both Phase 2a cohorts warrants full enrollment in their respective Phase 2b cohorts. Approximately, 30 response evaluable participants are enrolled in each of Phase 2a GC and EC arm. However, based on the prior experiences investigating anti-EGFR and anti-cMet antibodies in gastroesophageal cancers, at least 20 participants expressing IHC 2+ or higher (defined as participants expressing EGFR IHC 2+ or above or cMet IHC 2+ or above) are enrolled. Moreover, at least 10 participants expressing any level of cMet protein (IHC1+ or above) are enrolled in each Phase 2a cohort to better characterize the contribution of cMet in amivantamab activity. Additional enrollment may be allowed in the Phase 2a cohorts to achieve this minimal enrollment, if these criteria aren’t met in the initial 30 evaluable subjects. If activity is demonstrated in the Phase 2a cohorts, Phase 2a expansion cohorts investigating a maximum of 11 participants without any expression of EGFR and cMet, may open for enrollment. The Phase 2b GC expansion or EC expansion cohorts evaluate the antitumor activity of amivantamab in GC and EC patients, using biomarker selection based upon Phase 2a results. If activated, approximately 100 participants are enrolled in each of the Phase 2b cohorts.
[00260] The study includes a screening phase (Screening Phase (Pre- and Full Screening) Section), a treatment phase (Treatment Phase Section), and a follow-up phase (Follow-up Phase (Applicable to Phase 2b Only) Section).
Screening Phase (Pre- and Full Screening)
[00261] During the full screening period, participants are evaluated for eligibility for study participation. Participants complete all screening procedures within 28 days of CID 1. Pretreatment biopsy is collected for all participants in Phase 2a and Phase 2b. The screening period can be extended by 14 days if reporting of central tumor IHC results are not completed within the 28-day screening period. However, all other assessments still meet timing criteria relative to C1D1 or are repeated.
[00262] An optional pre-screening period is offered to facilitate molecular characterization of archived tumor biopsy sample. The participant may submit archival sample before completion of the previous therapy.
Treatment Phase
[00263] The treatment phase for a participant begins on C1D1 and continue as 28-day cycles until the end-of-treatment (EOT) visit, approximately 30 days after discontinuation of study treatment. This study is conducted in an outpatient setting. However, in-hospital observation, from C1D1 until C1D8 is permitted in the Phase 2a (including Phase 2a extension cohorts) to allow close monitoring. Study treatment continues until documented clinical or radiographic (RECIST Version 1.1) disease progression or until the participant meets another criterion for discontinuation of study treatment.
[00264] Disease assessments occur as close as possible to the start of treatment (baseline screening scans), 6 weeks (+1 week) after the first dose of study treatment, then eveiy 6 weeks (±1 week) for the first 12 months and then eveiy 12 weeks (±1 week) until objective radiographic disease progression or withdrawal of consent.
[00265] At each study visit during the treatment phase, participants undergo safety evaluations, including physical examinations and assessment of adverse events ( AEs), vital signs, concomitant medication usage, and clinical laboratory parameters. Participants also have blood samples drawn for assessment of PK and immunogenicity parameters and for biomarker evaluations, at selected visits. Post-treatment biopsy, circulating tumor DNA(ctDNA), and biomarker at C2D 15 as well as per the Schedule of Activities Section are collected on C2D 15 (+1 week) from all participants in Phase 2a.
Follow-up Phase (Applicable to Phase 2b Only)
[00266] Participants who discontinue study treatment are followed for subsequent therapy, disease status (applicable only if participants discontinuing treatment due to reasons other than progressive disease, to confirm disease progression date), and survival in the follow-up phase. This phase starts from the EOT visit assessment is done every 12 weeks (±14 days) after the last dose of study treatment or disease progression (whichever occurs first) and continues until the end of study, death, lost to follow-up, or withdrawal of consent from participation in the study, whichever comes first.
[00267] A diagram of the study design is provided in Figure 1.
Justification for Dose
[00268] Amivantamab was generally well tolerated in a Phase 1 study (Study
61186372EDI1001) up to the dose of 1750 mg, with no dose limiting toxicities reported during dose escalation and no maximum tolerated dose identified in lung cancer participants. Based on the totality of exposure, safety, and efficacy data, the recommended Phase 2 dose was determined to be 1050 mg for body weight <80 kg and 1400 mg for body weight >80 kg, administered by IV infusion in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. The recommended Phase 2 dose achieved a complete soluble target saturation throughout dosing for the EGFR and cMet in the lung cancer participants. The observed safety profile of amivantamab is consistent with EGFR and cMet inhibition and majority of treatment emergent adverse events (TEAEs) were Grade 1 to 2 in severity. Therefore, administering the same dosing regimen to GC or EC participants is considered appropriate.
Study Population
[00269] Screening for eligible participants is performed within 28 days before administration of the study treatment.
[00270] The inclusion and exclusion criteria for enrolling participants in this study are described below.
Inclusion Criteria
[00271] Each potential participant satisfies all of the following criteria to be enrolled in the study.
[00272] 1. Participant is >20 years of age (or the legal age of consent in the jurisdiction in which the study is taking place).
[00273] 2. Participant tumor express either EGFR, cMet, or both as determined by either local or central IHC assay (IHC 1+ or above). A copy of the de-identified pathology report for IHC analysis is submitted during the screening period if local IHC test was used for the eligibility determination. Phase 2a extension cohorts: Participant tumor lacks expression of EGFR and MET as determined by either local or central IHC assessment. A copy of the de-identified pathology report for IHC analysis is submitted during the screening period if local IHC test was used for the eligibility determination.
[00274] 3. Participant has histologically or cytologically confirmed gastric (including GEJ) or EC that is locally advanced, unresectable, or metastatic, and not eligible for curative treatment. [00275] Gastric or GEJ Cancer Only: Participant is refractory or ineligible to at least 2 prior lines of standard of care systemic therapy. Prior therapies include fluoropyrimidine- and platinum-based chemotherapy. Participants with known HER2 expression have had HER2- targeting therapy as part of the prior therapy. In case of progression within 24 weeks of prior adjuvant or neoadjuvant chemotherapy, this therapy is considered as 1 prior line of systemic therapy for the purpose of meeting the eligibility criteria.
[00276] Esophageal Cancer Only: (a) Participant is refractory or intolerant to at least 1 prior line of systemic therapy. Prior therapies include fluoropyrimidine-, and platinum-based chemotherapy (including chemoradiation therapy given as stage IV setting), (b) Participant who underwent a radical resection in conjunction with chemotherapy including neo- adjuvant/adjuvant therapy and chemoradiation (including participants who underwent chemoradiation, if residual tumor exists, followed by salvage surgery) whose recurrence was confirmed by imaging within 24 weeks after the last dose of chemotherapy are considered as having received 1 line of prior systemic therapy for the purpose of meeting the eligibility criteria. If prior combination therapy discontinued due to an AE, and then one of the agents continued, this is considered to be “1 prior line” and not “2 prior lines.” The change in dosage form (IV administration, oral administration) or dose reduction without progression is considered to be “1 prior line” and not “2 prior lines.”
[00277] 4. Participant has measurable disease according to RECIST Version 1.1. If only one measurable lesion exists, it may be used for the screening biopsy if the baseline tumor assessment scans are performed >7 days after the biopsy.
[00278] 5. Participant has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Eastern Cooperative Oncology Group (ECOG) Performance Status).
[00279] 6. Participant has adequate organ and bone marrow function as follows, without history of red blood cell transfusion or platelet transfusion within 7 days prior to the date of the laboratory test. a. Hemoglobin >8 g/dL b. Absolute neutrophil count >1500/mm3, without use of granulocyte colony stimulating factor (G-CSF) within 10 days prior to the date of the test
c. Platelets >75,000/mm3 d. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
<3xupper limit of normal (ULN). If liver metastases are present, <5xULN e. Total bilirubin <1.5xULN (participants with Gilbert’s syndrome can enroll if direct bilirubin is within normal limits) f. Calculated or measured glomerular filtration rate >40 mL/min using the Modified Diet in Renal Disease (MDRD) equation (refer to MDRD formula for eGFR)
[00280] 7. Participant has a tumor lesion amenable for biopsy and agree to protocol-defined mandatory biopsies.
Exclusion Criteria
[00281] Any potential participant who meets any of the following criteria are excluded from participating in the study.
[00282] 1. Participant has an uncontrolled illness, including but not limited to the following: a. Diabetes b. Ongoing or active bacterial infection (includes infection requiring treatment with antimicrobial therapy [participants are required to complete antibiotics 1 week before enrollment]), symptomatic viral infection, or any other clinically significant infection c. Active bleeding diathesis d. Psychiatric illness/social situation that would limit compliance with study requirements [00283] 2. Participant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or 4 half-lives whichever is longer or had radiation therapy within 4 weeks before the first administration of study treatment. For agents with long half-lives, the maximum required time since last dose is 28 days. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia or post-radiation skin changes [any grade], Grade <2 peripheral neuropathy, and Grade <2 hypothyroidism stable on hormone replacement).
[00284] 3. Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and of corticosteroid treatment for at least 2 weeks prior to the first administration of study treatment is eligible), history of leptomeningeal disease or spinal cord compression that has not been treated definitively with
surgery or radiation. If brain metastases are diagnosed on screening imaging, the participant may be rescreened for eligibility after definitive treatment.
[00285] 4. Participant has a history of(non-infectious) ILD/pneumonitis that required steroids, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Esophageal cancer participants with history of completely resolved radiation pneumonitis (defined as radiographically stable for 3 months prior to enrollment without need of any treatment) may be enrolled.
[00286] 5. Participant has an active malignancy (i.e., progressing or requiring treatment change in the last 12 months) other than the disease being treated under study. The only allowed exceptions are: a. Non-muscle invasive bladder cancer treated within the last 24 months that is considered completely cured. b. Skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured. c. Non-invasive cervical cancer treated within the last24 months thatis considered completely cured. d. Localized prostate cancer (N0M0):
• With a Gleason score of 6, treated within the last 24 months or untreated and under surveillance,
• With a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence,
• Or history of localized prostate cancer and receiving androgen deprivation therapy and considered to have a very low risk of recurrence. e. Breast cancer:
• adequately treated lobular carcinoma in situ or ductal carcinoma in situ,
• or history of localized breast cancer and receiving antihormonal agents and considered to have a very low risk of recurrence. f. Malignancy that is considered cured with minimal risk of recurrence. g. Phase 2a participants only: Participants with a second mal ignancy may enroll if any systematic treatment is considered not to become necessary for at least 6 months after the enrollment.
[00287] 6. Participant has a history of clinically significant cardiovascular disease including, but not limited to: a. Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to the first dose of study treatment or any of the following within 6 months prior to the first dose of study treatment: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically nonsignificant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary. b. Prolonged QTcF interval >480 msec or clinically significant cardiac arrhythmia or electrophysiologic disease (eg, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate). Participants with cardiac pacemakers who are clinically stable are eligible. c. Uncontrolled (persistent) hypertension: systolic blood pressure >180 mm Hg; diastolic blood pressure >100 mm Hg. d. Congestive heart failure defined as New York Heart Association (NYHA) class III-IV or Hospitalization for congestive heart failure (any NYHA class) (New York Heart Association Criteria) within 6 months of study enrollment. e. Pericarditis/clinically significant pericardial effusion. f. Myocarditis.
[00288] 7. Participant has known allergies, hypersensitivity, or intolerance to excipients of amivantamab.
[00289] 8. Participant has received study treatment (including investigational vaccines) within 6 weeks before enrollment except for the anticancer therapy described in the Exclusion Criterion No. 2.
[00290] 9. Participant has, or is expected to have, any of the following: a. An invasive operative procedure with entry into a body cavity, within 4 weeks or without complete recovery before C1D1. Thoracentesis, if needed, and percutaneous biopsy for basefine tumor tissue sample may be done less than 4 weeks prior to CID 1, as long as the participant has adequately recovered from the procedure prior to the first dose of study treatment in the clinical judgement of the investigator b. Significant traumatic injury within 3 weeks before the start of C1D1 (unless all wounds are fully healed prior to Day 1 )
c. Expected major surgery while the investigational agent is being administered or within
6 months after the last dose of study treatment
[00291] 10. Participant has at screening: a. Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg). Participants with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at screening 1) a negative HBsAg and 2) an HBV DNA (viral load) below the lower limit of quantification, per local testing. Participants with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing. b. Positive hepatitis C antibody (anti-HCV [hepatitis C virus]). Participants with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible. c. Other clinically active infectious or non-infectious fiver disease
[00292] 11. Participant is known to be positive for human immunodeficiency virus (HIV), with
1 or more of the following: a. Not receiving highly active antiretroviral therapy (ART) b. Had a change in ART within 6 months of the start of screening c. Receiving ART that may interfere with study treatment d. CD4 count <350 at screening e. Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within
6 months of start of screening. Not agreeing to start ART and be on ART >4 weeks plus having HIV viral load <400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled).
[00293] 12. Participant has received prior EGFR or cMet-directed therapies.
Activity
[00294] Participants agree to use sun protective measures (such as a hat, sunglasses, protective clothing, sunscreen), limit prolonged exposure to natural sunlight, and avoid artificial sunlight (tanning beds or phototherapy) from baseline until the last dose of study treatment. Use broadspectrum sunscreen (containing titanium dioxide or zinc oxide) with a skin protection factor >15.
Study Treatment Administered
[00295] Amivantamab is supplied for this study in a glass vial containing 350 mg/vial with concentration of 50 mg/mL in a 7 mL vial. The IV infusion is prepared at the site in 250 mL of diluent.
[00296] The initial dosage of amivantamab is based on the participant's body weight at screening: 1,050 mg (if body weight is <80 kg) or 1,400 mg (if body weight is >80 kg), s Amivantamab is administered as an IV infusion in 28-day cycles as follows:
Cycle 1 : Once weekly (with the first dose split over Day 1 [350 mg] and Day 2 [700 mg if body weight is <80 kg or 1,050 mg if body weight is >80 kg]).
Cycles 2+: Days 1 and 15 of each cycle.
[00297] Amivantamab may be administered at a higher dose based on body weight: 1750 mg for body weight <80 kg and 2100 mg for body weight >=80 kg as IV infusion in 28-day cycles as follows:
Cycle 1 : Once weekly (with the first dose split over Day 1 [350 mg] and Day 2 [ 1400 mg if body weight is <80 kg or 1,750 mg if body weight is >80 kg]).
Cycles 2+: Days 1 and 15 of each cycle.
[00298] Amivantamab is administered intravenously using an escalating infusion rate regimen.
The product is infused via a peripheral vein for all Cycle 1 doses; infusion via central line is allowed for subsequent dosing starting with the C2D1 dose.
[00299] Amivantamab is administered according to clinical protocol. Additional guidance is provided below:
• On Day 1 of each cycle, results of hematology and chemistry laboratory assessments are reviewed before administering study treatment.
• Amivantamab is diluted prior to infusion
• Amivantamab is not mixed or diluted with other drugs.
• Amivantamab is not administered as an IV push or bolus.
[00300] Dose and administration schedule may be adjusted during this study.
Preparation/Handling/Storage/Accountability
Preparation/Handhng/Storage
[00301] All study treatment are stored at controlled temperatures according to the requirements on the label. Amivantamab is protected from light prior to use.
Measures to Minimize Bias: Randomization and Blinding
Treatment Allocation
[00302] Procedures for Randomization: Randomization is not used in this study. Participants are assigned to treatment in the order in which they qualify for this study.
Blinding
[00303] As this is an open-label study, blinding procedures are not applicable.
Dose Delay Guidance
[00304] In instances where treatment delay is indicated, treatment with amivantamab may be delayed until recovery of toxicity to a level allowing continuation of therapy. A participant for whom treatment was delayed is assessed at least weekly to ensure adequate supportive care is being administered and to assess for improvement of toxicity. For majority of clinically significant toxicities withholding doses and dose modifications may be made as per the guidelines described below (Dose Modification Guidance Section).
[00305] The following sections provide additional guidance for the prevention, monitoring, and management of toxicities that have been reported with amivantamab.
Infusion-related Reactions
[00306] Infusion-related reactions have been commonly observed during treatment with amivantamab, predominantly with the first exposure on CID 1, and typically within the first 90 minutes of the infusion. The majority of IRRs are Grade 1 or 2. The guidelines described here are related to the safe administration of amivantamab during initial dosing.
[00307] During the amivantamab infusions, participants are clinically monitored at regular intervals (including an assessment prior to the start of infusion). The monitoring includes heart rate, blood pressure, temperature, respiratory rate, and oxygen saturation measurements.
Amivantamab Pre-infusion and Post-infusion Medications
Amivantamab Pre-infusion Medications
[00308] Required and optional amivantamab pre-infusion medications for IRRs are summarized in Table 3.
C=Cycle; D=Day X; IV=intrav enous. a. If a medication noted in this table is not locally available, a similar medication and dose may be substituted and administered per local guidelines. b. Participants for whom required medications are contraindicated may explore alternative medications with their study physician. If alternative medications are not suitable for the intent above, participants are not required to take the corresponding medication. c. Beginning with C1D8, optional predose steroids may be administered if clinically indicated for participants who experiencedaninfusion-relatedreactiononClDl orC!D2.
Amivantamab Post-infusion Medications
[00309] Optional amivantamab post-infusion medications may be prescribed and continued for up to 48 hours after the infusion if clinically indicated as described in Table 4.
IV =intravenous . a. Optional medications can be used prophylactically as clinically indicated. If a medication noted in this table is not locally available, a similar medication and dose may be substituted and administered per local guidelines
Prohibited or Restricted Medications and Therapies
[00310] The following concomitant medications and therapies are not used during the study.
• Any chemotherapy, systemic anticancer therapy, or experimental therapy (other than study treatments). Hormonal treatments as specified in exclusion 5 are allowed.
• Radiotherapy to tumor lesions being assessed for tumor response prior to radiographic progression
• Use of live or five attenuated vaccines is prohibited
• Due to the potential for hypomagnesemia associated with EGFR inhibitors, concomitant medications that may decrease serum magnesium are avoided if possible.
Study Assessments and Procedures
Overview
[00311] The Schedule of Activities Section summarizes the frequency and timing of the measurements applicable to this study.
[00312] The total blood volume collected for the study is approximately 25 mL (screening), 105 mL (Cycle 1), 75 mL (Cycle 2), and 30 mL (for each cycle beyond Cycle 3 and EOT).
[00313] Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples.
Efficacy and Immunogenicity Assessments
Disease Assessments
[00314] Disease assessments are performed as described in the Schedule of Activities (Table 1 ) regardless of any dose modifications. More frequent radiologic assessments are allowed if clinically indicated.
[00315] Computerized tomography scan of the chest (including the supraclavicular region), abdomen, pelvis, and any other disease location(s), if clinically indicated, is performed with an IV contrast agent. Participants not able to undergo CT scans with IV contrast (e.g., due to allergy or renal insufficiency) may have non-contrast CT of the thorax and MRI of the abdomen and pelvis with IV contrast at baseline and during the study. Identical methodology is used for disease assessment at baseline and throughout the course of the study to characterize each identified and reported lesion to document disease status. Techniques other than CT or MRI may
be used based upon local standard of care, and RECIST Version 1.1 guidelines for the use of these alternative techniques.
[00316] The baseline disease assessments are performed as close as possible to the start of treatment, but no more than 28 days prior to the first dose. Subsequent assessments are performed at 6 weeks (+ 1 week) after initiation of study treatment administration, then every 6 weeks (±1 week) for the first 12 months and then every 12 weeks (±1 week) until objective radiographic disease progression. Timing for each disease assessment is relative to the first dose of study treatment administration, regardless of dose modifications, and continues until disease progression. Any other site at which new disease is suspected is also imaged.
[00317] If a participant achieves partial response (PR) or complete response (CR), the response is confirmed after, but as close to, 4 weeks of entering PR or CR instead of predefined 6 weeks. [00318] If it is unclear as to whether progression has occurred, particularly with response to nontarget lesions or the appearance of a new lesion, treatment is continued until the next scheduled assessment (or sooner if clinically indicated) and reassess the participant’s status. If the repeated scans confirm progression, then the date of the initial scan is declared as the date of progression. To achieve “unequivocal progression” on the basis of non target lesions, there must be an overall substantial worsening in nontarget lesions such that, even in the presence of stable disease or PR in target lesions, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest “increase” in size of 1 or more nontarget lesions is usually not sufficient to qualify for unequivocal progression. If symptomatic deterioration (on the basis of global deterioration of health status) is recorded as the basis for determining disease progression, then the clinical findings used to make the determination are specified.
Radiographic progression is documented even after discontinuation of treatment for symptomatic deterioration, but prior to subsequent therapy, if possible. For participants who discontinue study treatment due to toxicity or a reason other than objective progressive disease, tumor assessments is continued per schedule until radiographic progressive disease is documented.
[00319] Participants have brain MRI scan (CT scan with contrast may also be used to determine the presence of brain lesions if MRI is contraindicated) at screening to identify any untreated brain metastases (Exclusion criterion #3). Brain scan is not required with every subsequent disease assessment, regardless of history of prior brain metastases, and is performed if clinically indicated, according to local guidelines and practices.
[00320] If a participant is deriving clinical benefit and treatment beyond documented disease progression is approved, disease assessments continues as scheduled and clinical benefit after each disease assessment is reviewed.
Safety Assessments
[00321] Any clinically significant abnormalities persisting at the end of the study/early withdrawal are followed until resolution or until a clinically stable condition is reached.
[00322] The study includes the following evaluations of safety and tolerability according to the time points provided in the Schedule of Activities Section.
Physical Examinations
[00323] The screening physical examination includes, at a minimum, the participant’s height, weight, and general appearance and an examination of the skin, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system. On Day 1 of each cycle, directed physical examinations of involved organs and other body systems, as indicated, are performed and participant body weight is obtained using a calibrated scale.
Vital Signs
[00324] Vital sign measurements include the following assessments as indicated in the Schedule of Activities (Table 1):
• Temperature
• Heart rate
• Respiratory rate
• Oxygen saturation
• Blood pressure
[00325] Blood pressure and heart rate measurements are assessed in a seated position with a completely automated device. Manual techniques are used only if an automated device is not available.
[00326] Blood pressure and heart rate measurements are preceded by at least 5 minutes of rest in a quiet setting without distractions (e.g., television, cell phones).
Electrocardiograms
[00327] Triplicate electrocardiograms (ECGs), performed locally, are collected at screening to determine the eligibility. During the collection of ECGs, participants are in a quiet setting without distractions (e.g., television, cell phones). Participants rest in a supine position for at
least 5 minutes before ECG collection and are refrain from talking or moving arms or legs. If blood sampling or vital sign measurement is scheduled for the same time point as ECG recording, the procedures are performed in the following order: ECG(s), vital signs, blood draw. [00328] Three individual ECG tracings are obtained as closely as possible in succession, but approximately 2 minutes apart. The ECG, including ECG morphology, is reviewed for immediate management.
[00329] QTcF is calculated using the Fridericia's formula: QTcF = QT/(RR)A0.33.
ECOG Performance Status
[00330] Eastern Cooperative Oncology Group performance status score is evaluated during the screening phase to determine the eligibility.
Clinical Safety Laboratory Assessments
[00331] Clinical laboratory assessments are performed locally. Clinical laboratory tests are performed as noted in Table 5.
[00332] More frequent clinical laboratory tests may be performed as indicated by the overall clinical condition of the participant or abnormalities that warrant more frequent monitoring. [00333]
Pharmacokinetics
[00334] Blood samples are used to evaluate the PK of amivantamab. Serum collected for PK may additionally be used to evaluate safety or efficacy aspects that address concerns arising during or after the study period. Evaluations
[00335] Blood samples are collected for measurement of serum amivantamab for PK analyses. The PK profile of amivantamab is based on serum concentration data obtained from the timepoints surrounding the first and fifth dose administrations collected from at least 10 participants in each cancer type in Phase 2a. Blood samples for sparse PK is also obtained following all other dose administrations from participants in Phase 2a and 2b, prior to the start of the infusion and following the end of the infusion, from all the participants. Analytical Procedures
[00336] Pharmacokinetics: Serum samples are analyzed to determine concentrations of amivantamab using a validated, specific, and sensitive enzyme-linked immunosorbent assay (ELISA) method.
[00337] In addition, serum PK samples may be stored for future analysis of other coadministered treatments.
Pharmacokinetic Parameters and Evaluations
[00338] The primary PK endpoints include, but are not limited to maximum serum concentration (Cmax), Tmax, AUC(ti-t2) (e.g., AUCoayi-s), AUCtau, plasma/serum concentration immediately prior the next study treatment administration (Ctrough), ti/2, CL, steady state volume of distribution (Vss), and accumulation ratio. Population PK modeling may be performed to assess the potential effect of intrinsic factors and extrinsic on the PK of amivanatamab. Biomarkers
[00339] Collected tumor tissue samples are used to evaluate the tumor surface levels of EGFR and cMET protein expression by centrally performed IHC assay to determine the patient eligibility, although documentation of previously performed local IHC results may be submitted for the purposes of demonstrating eligibility for study conduct. All statistical and biomarker analysis, however, utilize the results of the centrally performed IHC results, which classify patients as 0, 1+, 2+ or 3+ based on the highest staining of either EGFR or cMet. Tumor tissue collected at screening may also be analyzed by tumor next-generation sequencing to evaluate molecular alterations and track response to treatment. Tumor samples collected post-treatment and post-progression may also be evaluated by IHC and next-generation sequencing to track response to amivantamab. Tissues may also be used to determine biomarkers relevant to GC/EC and/or analyzed to confirm ctDNA results.
[00340] Screening blood samples from all participants undergo ctDNA analysis to evaluate pretreatment mutational status of EGFR, cMet, and other key oncogenes to characterize the tumor. Additional blood samples are collected during the study and may be evaluated for ctDNA to assess changes in the levels or types of genetic alterations observed over time and to monitor for the emergence of potential markers of resistance to amivantamab.
[00341] Blood samples are also collected at time points and may be analyzed for circulating factors relevant to disease biology (e.g., hepatocyte growth factor).
[00342] Blood samples are also collected from at least 10 participants in each cancer type at selected time points to analyze PD markers (e.g., soluble EGFR and cMet) in samples taken prior to and after exposure to amivantamab, to explore whether the complete soluble target saturation throughout the dosing was attained.
[00343] For the provision of biopsy tissue samples, formalin-fixed, paraffin-embedded (FFPE) tissue samples are requested and are evaluated for biomarkers (DNA, RNA, and/or protein) relevant to cancer.
Immunogenicity Assessments
[00344] Serum samples are collected for immunogenicity assessments of amivantamab (antidrug antibodies to amivantamab). The detection and characterization of antibodies to amivantamab is performed using a validated immunoassay method.
[00345] Serum samples are screened for antibodies binding to amivantamab and serum titer is determined from positive samples. Antibodies may be further characterized and/or evaluated for
their ability to neutralize the activity of the study treatment. All samples collected for immune response analysis are also evaluated for amivantamab serum concentration to ensure appropriate interpretation of immunogenicity data. Other immunogenicity analyses may be performed to further characterize any immune responses generated.
Statistical Considerations
[00346] A general description of the statistical methods to be used to analyze the efficacy and safety data is outlined below.
Statistical Hypotheses
[00347] No hypothesis is planned to be tested in Phase 2a.
[00348] The statistical hypothesis in Phase 2b is that amivantamab monotherapy leads to objective response rate (ORR) higher than 15% (i.e., Ho <15% vs Ha >15%) in patients with GC or EC, selected on the basis of expression of EGFR, cMET, or both. This threshold is based on historical studies for approved 3L regimens for GC (11.2%-13.6%) and reported efficacy of approved 2L regimens for EC (approximately 15%).
Sample Size Determination
[00349] In Phase 2a, approximately 30 response evaluable participants with tumors expressing either EGFR, cMet, or both, as determined by central IHC, are enrolled in GC and EC cohorts. Twenty participants are enrolled for IHC 2+/3+ that provides approximately 90% probability to observe the posterior probability of (ORR >22.5%) >40% (which is similar with ORR >20%) assuming ORR is 30% for the subpopulation. By enrolling 10 participants with IHC 1+, the probability to observe the posterior probability (ORR >22.5%) >40% is 80%. A maximum of 11 participants may be enrolled in each Phase 2a extension cohort. Enrollment halts if no response or stable disease of 6 weeks or more is observed among the first 6 participants for futility in each of the Phase 2a extension cohorts. If 2 or more responses are observed in each of Phase 2a extension cohorts, Additional participants may be enrolled for further characterization.
[00350] In Phase 2b cohorts, approximately 100 participants are enrolled in each of GC and EC expansion cohort. The eligible participants are decided based on the results in Phase 2a part. Assuming an overall ORR of 30% for amivantamab, 100 participants in Phase 2b part provides approximately 90% power to reject the null hypothesis, 15% ORR, using 2-side z test at alpha=0.05.
Populations for Analysis Sets
[00351] For purposes of analysis, the following populations are defined:
(1) All Treated population: All participants who take at least 1 dose of study treatment;
(2) Response evaluable population: All participants who satisfy the following criteria:
• Receive at least 1 dose of study treatment;
• At least 2 post-baseline efficacy disease assessments, or discontinued treatment for any reason, or have disease progression/death prior to the second post-baseline disease assessment;
(3) Safety population: All participants who take at least 1 dose of study treatment;
(4) Pharmacokinetics population: All participants who receive at least 1 dose of study treatment and have at least 1 evaluable post-baseline measurement;
(5) Immunogenicity population: All participants who receive at least 1 dose of study treatment and have at least 1 evaluable post-baseline measurement.
General Considerations
[00352] All continuous variables are summarized using number of participants (n), mean, standard deviation (SD), median, minimum, and maximum. Discrete variables are summarized with number and percent. The Kaplan-Meier product limit method is used to estimate the time- to-event variables including median survival time. Unless otherwise specified, the phases and arms are analyzed separately.
[00353] Analyses of ORR and disease control rate (DCR) is performed on the response evaluable population. The other efficacy analyses are performed on all treated population. The central IHC data are used for the statistical analysis purposes.
[00354] At the end of Phase 2a part, the result are reviewed and which subpopulations to be included in the Phase 2b part are determined.
Primary Endpoint
[00355] Objective Response Rate. Primary Estimand:
• Population: participants with GC or EC expressing EGFR and/or MET
• Variable: overall response; CR or PR
• Study drug: amivantamab monotherapy
• Intercurrent event: subsequent anticancer therapy. The while-on-treatment policy: Response after this intercurrent event is not included.
• Summary: ORR
[00356] The primary efficacy measure is ORR. Objective response rate is defined as the proportion of participants who achieve either CR or PR, determined by investigator assessment using RECIST Version 1.1. Confirmation of investigator-assessed ORR may be performed through IRC in the Phase 2b.
[00357] For Phase 2a part, there is no formal hypothesis testing. ORR is calculated for response evaluable population descriptively.
[00358] For Phase 2b part, a z test with normal approximation is used to compare the ORR with 15%. Multiplicity caused by subpopulation selection at the interim analysis (see Interim Analysis Section) is controlled by closed testing procedure and weighted statistics. The ORR and its 95% confidence interval (CI) are also calculated.
Secondary Endpoints
[00359] Disease Control Rate: Disease control rate is defined as the percentage of participants achieving complete or partial response or stable disease for at least 6 weeks as defined by RECIST Versionl.l. The DCR and its 95% CI with Clopper-Pearson method are also calculated. [00360] Duration of Response: Duration of Response (DoR) is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first. The end of response would coincide with the date of progression or death from any cause used for the PFS endpoint. If a participant does not progress following a response, then his/her duration of response uses the PFS censoring time. A Kaplan-Meier plot and median DoR with 95% confidence interval (calculated from the Kaplan-Meier estimate) are presented. Confirmation of investigator-assessed DoR may be performed through IRC in the Phase 2b.
[00361] Progression-free Survival: Progression-free survival is defined as the time from first dose until the date of objective disease progression or death (by any cause in the absence of progression), whichever comes first, based on investigator assessment using RECIST Version 1.1. Participants who have not progressed or have not died at the time of analysis are censored at
the time of the latest date of assessment from their last evaluable RECIST Version 1.1 assessment. PFS is analyzed using the same methodology as for the analysis of DoR.
[00362] Overall Survival: Overall survival is defined as the time from the date of first dose until the date of death due to any cause. Any participant not known to have died at the time of analysis are censored based on the last recorded date on which the participant was known to be alive. OS is analyzed using the same methodology as for the analysis of DoR.
Other Analyses
Pharmacokinetic Analyses
[00363] The PK analyses use the PK population. Serum amivantamab concentrations are summarized for each cancer type and overall population in tables of mean, SD, median, and range over time, as appropriate. PK parameters are estimated for individuals and descriptive statistics are calculated for each cancer type and overall population.
[00364] Participants are excluded from the PK analysis if their data do not allow for accurate assessment of the PK (e.g., incomplete administration of the study treatment; missing information of dosing and sampling times; concentration data not sufficient for PK parameter calculation).
Pharmacokinetic/Pharmacodynamic Analyses
[00365] The exposure -response relationship between amivantamab exposure and key efficacy and safety parameters may be explored if the data allow. In addition, the relationship may be characterized using an exposure-response model.
Immunogenicity Analyses
[00366] The incidence of anti- amivantamab antibodies is summarized for immunogenicity population.
[00367] Serum samples are screened for antibodies binding to amivantamab and the number of confirmed positive samples are reported. Other analyses may be performed to further characterize the immunogenicity of amivantamab.
Pharmacodynamic and Biomarker Analyses
[00368] The biomarker analyses use the biomarker population. Analyses are planned to explore PD and other biomarkers that may be indicative of the mechanisms of action of the drug or predictive of efficacy as well as the potential mechanisms of resistance to amivantamab.
[00369] The association of biomarker-positivity with clinical response or time-to-event endpoints is assessed using statistical methods appropriate for each endpoint (eg, analysis of variance, categorical, or survival models). Correlation of baseline biomarker expression levels with clinical response or relevant time to-event endpoints is performed to identify responsive (or resistant) subgroups.
[00370] Additional biomarkers (DNA, RNA, and/or protein) relevant to GC/EC may also be assessed in blood and tissue samples collected during the study to better understand the disease and mechanisms of response or resistance to amivantamab.
Interim Analysis
[00371] In Phase 2b, an interim futility analysis is planned in each of GC and EC arm approximately 12 weeks after 50 participants receive the first infusion. The interim futility analyses is based on the best response rate for each subpopulation (for example, IHC 2+/3+ and IHC 1+) selected at the end of Phase 2a and prespecified before initiating Phase 2b). The enrollment of each subpopulation may be terminated for futility if the posterior probability (ORR >22.5%) is <40%.
Results.
[00372] Participants in Phase 2a gastric cancer (GC) and esophageal cancer (EC) cohorts received intravenous (IV) infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight less than (<) 80 kilograms (kg) received IV infusion of amivantamab 1 ,050 milligrams (mg) and participants with body weight greater than or equal to (>) 80 kg received IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle). The enrollment status is shown in Table 6. The demographics and disease characteristics are shown in Table 7. The overall safety summary of treatment emergent adverse events (TEAEs) are shown in Table 8. The TEAEs related to grade 3 or higher are shown in Table 9.
[00373] The observed incidence of infusion related reactions (IRRs) was similar to other amivantamab monotherapy studies. The incidence of hypoalbuminemia in the gastric cohort was slightly higher than that of esophageal cohort:
[00374] Gastric (n=29): All grade: 12 (41.4%), > Grade 3: 3 (10.3%)
[00375] Esophageal (n=30): All grade: 10 (33.3%), > Grade 3: 3 (10.0%)
[00376] Next, response to treatment was evaluated. The “All Treated” patient population were patients who received at least 1 dose of study treatment. The “Response Evaluable” patient population were patients who ( 1 ) received at least 1 dose of study treatment, (2) met all eligibility criteria for the study, and (3) had a baseline and at least 1 post-baseline efficacy disease assessments, or have disease progression/death due to disease progression prior to the first post-baseline disease assessment. Table 10 shows summary of objective response rate based on RECIST Version 1.1 criteria by pre-screening IHC Score (Central) in response evaluable population. Table 11 shows summary of objective response rate based on RECIST Version 1.1 criteria by pre-screening IHC score (Central) in all treated population.
[00377]
Table 10. Summary of Objective Response Rate Based on RECIST Version 1.1 Criteria by Pre-screening IHC Score (Central) - Investigator Judgement (Response evaluable population)
Key: CI = confidence interval a For a response to qualify as stable disease, follow-up measurements must have met the stable disease criteria at least once at a minimum interval >6 weeks after the first dose of study agent. b The exact Clopper-Pearson 95% CI is used. c The Posterior probability (ORR >22.5%) is calculated based on beta distribution.
Note: A response of PR or CR must be confirmed by repeat assessments >4 weeks from the initial observation.
Note: IHC score is defined as the highest staining of either EGFR or cMet.
Table 11. Summary of Objective Response Rate Based on RECIST Version 1.1 Criteria by
Key: CI = confidence interval a For a response to qualify as stable disease, follow-up measurements must have met the stable disease criteria at least once at a minimum interval >6 weeks after the first dose of study agent, b The exact Clopper-Pearson 95% CI is used. c The Posterior probability (ORR >22.5%) is calculated based on beta distribution.
Note: A response of PR or CR must be confirmed by repeat assessments >4 weeks from the initial observation.
Note: IHC score is defined as the highest staining of either EGFR or cMet.
[00378] The overall response for gastric cancer patients in response evaluable population is shown in Figure 6. The overall response for gastric cancer patients in all treated population is shown in Figure 7. The overall response for esophageal cancer patients in response evaluable population is shown in Figure 8. The overall response for esophageal cancer patients in all treated population is shown in Figure 9.
[00379] In summary, safety profile in gastric / esophageal cancer cohorts is consistent with reported experience of other amivantamab monotherapy studies. Gastric cancer cohort had 1 partial response, 5 stable disease patients (disease control rate (DCR): 25.0%) among 24 response evaluable patients. Esophageal cancer cohort had 3 partial responses and 16 stable disease patients (DCR: 67.9%) among 28 response evaluable patients.
[00380] Higher dose of 1,750 mg amivantamab was evaluated in 3 patients with esophageal cancers. All 3 participants had body weight less than (<) 80 kilograms (kg) and received IV infusion of amivantamab 1,750 mg once weekly in Cycle 1, having the 1st dose split over Day 1 and Day 2 as 350 mg and 1400 mg respectively, and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle). Table 12 shows demogrphic data and disease characteristics in patients trated with 1,750 mg amivantamab. Table 13 shows overall safety summary of TEAEs in patients trated with 1,750 mg amivantamab. No grade 3 or higher TEAEs were observed in the 1,750 mg amivantamab population.
Table 12. Demographics and disease characteristics
[00381] Efficacy was evaluated in 3 patients treated with 1750 mg amivantamab. One patient had stable disease, one had partial response, and one had progressing disease. Figure 10 shows the best overall response in response evaluable patients.
Example 2. Evaluation of amivantamab in esophageal patient-derived xenograft models (PDX) models expressing wild-type EGFR
[00382] To evaluate the efficacy of amivantamab in a series of esophageal PDX models (n=12, provided by CrownBio) carrying wild-type EGFR, tumor fragments from stock tumor bearing mice were harvested and inoculated into indicated experiment mice. Each mouse was inoculated subcutaneously in the right flank with indicated tumor fragments (2-3 mm in diameter) for tumor development. Detailed esophageal PDX inoculation information is listed in Table 14.
Table 14.
[00383] After establishment of palpable lesions, the tumor growth was measured twice weekly. Once the mean tumor volume reached approximate 150 mm3, animals were randomly allocated to relevant study groups with 8 mice per group. The randomization was performed according to the tumor size of each group, and the day of randomization was denoted as DayO. The treatments were started on the same day of randomization per study design in Table 15.
[00384] The study endpoints were to compare the tumor growth in each group at the end of treatments, and the subsequent tumor outgrowth after dosing stopped. The tumor size was measured twice weekly in two dimensions using a caliper, and the tumor volume was expressed in mm3 using the formula V= 0.5xLxW2, where V is tumor volume, L is tumor length (longest tumor dimension) and W is tumor width (longest tumor dimension perpendicular to L). The tumor growth curves (expressed as Mean ± SEM) over time are shown in Figures 2A-2L.
[00385] Tumor growth inhibition (TGI%) was an indication of anti-tumor activity and calculated as TGI% = (l-(T-T0)/(C-C0)) x 100%, T and C were the mean tumor volume (TV) of treated and control groups, respectively on the day when mean TV of control group were terminated per study design. Tumor growth inhibition is summarized in Table 16.
[00386] As shown in Figures 2A-2L and Table 16, 7 out of 12 esophageal PDX tumors responded to amivantamab mono-treatment. Among these, amivantamab induced regression of tumors in ES3431 (TGI% 112.7%) and ES0178 (TGI% 100.4%), strongly inhibited tumor growth in ES0110 (TGI% 90.8%) and ES11079 (TGI% 94.5%), and moderate response in ES0026, ES3862 and ESI 1062 (TGI% 58.6%, 49.4%, and 45.5% respectively).
Example 3. Evaluation of amivantamab single agent or in combination with chemo-drugs or capmatinib in the treatment of gastric PDX tumors
[00387] To evaluate the anti-tumor activity of amivantamab, a panel of gastric PDX models were selected for treatment with amivantamab alone, or in combination with c-Met inhibitor
capmatinib (Selleck), as well as gastric chemo-regimens, such as 5-FU (Shanghai Xudong Haipu Pharm) plus cisplatin (Qilu Pharm), or paxlitaxel (Beijing Union Pharm).
[00388] Tumor fragments from stock tumor bearing mice were harvested and inoculated into BALB/c nude mice. Each mouse was inoculated subcutaneously in the right flank with indicated tumor fragments (2-3 mm in diameter) for tumor development. Detailed gastric PDX information is listed in Table 17.
[00389] After establishment of palpable lesions, the tumor growth was measured twice weekly. Once the mean tumor volume reached approximate 150 mm3, animals were randomly allocated to relevant study groups with 8 mice per group. The randomization was performed according to the tumor size of each group, and the day of randomization was denoted as DayO. The treatments were started on the same day of randomization according to the dosing regimen in Table 18 where appropriate.
QW: once weekly; BIW: twice weekly (DayO, 3 per week); BID: twice daily with 12 hours interval; QD, 5 days/week: once daily from DayO-5 per week.
*: GA0046 was treated with group 1,2, 7, 8; GA0075 and GA0152 were treated with group 1-6 (15 mg/kg paclitaxel); GA3121 was treated with group 1,2, 5, 6 (10 mg/kg paclitaxel); GA2254 and GA3236 were treated with group 1-2.
[00390] The study endpoints were to compare the tumor growth in each group at the end of treatments, and the subsequent tumor outgrowth after dosing stopped. The tumor size was measured twice weekly in two dimensions using a caliper, and the tumor volume was expressed in mm3 using the formula V= 0.5xLxW2, where V was tumor volume, L was tumor length (longest tumor dimension) and W was tumor width (longest tumor dimension perpendicular to L). Tumor growth curves (expressed as Mean ± SEM) over time are shown in Figures 3A-3F. [00391] Tumor growth inhibition (TGI%) was an indication of anti-tumor activities, and calculated as TGI% = (l-(T-T0)/(C-C0)) x 100%, T and C were the mean tumor volume (TV) of treated and control groups, respectively on the day when mean TV of control group were terminated per study design. Tumor growth inhibition are summarized in Table 19.
[00392] As shown in Figures 3A-3F and Table 19, amivantamab mono-treatment (10 mg/kg BIW) inhibited tumor growth in 3 out of 6 PDX models with strong anti-tumor activity observed in GA0046 (TGI% 121.31%) and GA0075 (101.17%).
[00393] In GA0046 (Figure 3A), full tumor regression was observed with amivantamab single agent. In comparison, a c-Met inhibitor capmatinib (10 mg/kg BID) showed no effect on tumor growth (TGI%: 5.93% on Day28).
[00394] Standard of care chemo regimens were also evaluated in this study. As shown in Figure 3B, 5-FU (10 mg/kg QD 5 days/week) plus cisplatin (4 mg/kg QW), or paclitaxel (10/15 mg/kg, QW) showed moderate activity, 43.35% and 66.09% on Day28 in GA0075. Strikingly, amivantamab combination elicited strong and long-lasting tumor growth inhibition in the same model (104.92% and 111.54% respectively). Similar synergistic effect between amivantamab and paxlitaxel was observed in another model GA0152, TGI% was improved from 27.29% to 70.13% (Figure 3E).
Example 4. Relationship between receptor expression and amivantamab in vivo efficacy in esophageal and gastric PDX tumors
[00395] To further study anti-tumor activity of amivantamab versus the receptor level, immunohistochemistry assay was performed to examine membrane expression of both EGFR and c-Met. Paraffin-embedded tissues were sectioned into 4 pm slides and placed in an
automatic staining system (Leica or Ventana). After a series of pre-set procedures (Dewax, peroxide block, primary antibody incubation, secondary antibody incubation, DAB reaction), stained slides (either with EGFR antibodies, clone 5B7 from Ventana or SP84 from Abeam, or with c-Met antibodies, clone SP44 from Ventana or Abeam) were further scanned with an image system (NanoZoomer) into high-resolution pictures for pathologist review and scoring.
[00396] The intensity of EGFR or c-Met membrane staining from each slide was scored at four levels: 0, 1+, 2+, and 3+. Further H-score was calculated based on percentage of cells at different intensity levels with below equation. Relative EGFR and c-Met H-scores in tested esophageal and gastric PDX models, together with anti-tumor activities of amivantamab, were listed in Table 20, Figure 4, and Table 21, Figure 5, respectively. In the esophageal tumors, high EGFR levels appear to be associated with the tumor growth inhibition (TGI%), where in gastric tumors, high levels of EGFR and/or cMet appear to be associated with amivantamab TGI%.
H-Score (0-300) = (%@0) x 0 + (%@1) X 1 + (%@2) x 2 + (%@3) X 3 %@0: percentage of cells with intensity 0 (negative staining).
%@ 1: percentage of cells with intensity 1+ (weak or incomplete membrane staining).
%@2: percentage of cells with intensity 2+ (weak-to-moderate complete membrane staining).
%@3: percentage of cells with intensity 3+ (strong complete membrane staining).
* * *
[00397] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
[00398] All patents, applications, publications, test methods, literature, and other materials cited herein are hereby incorporated by reference in their entirety as if physically present in this specification.
Claims
Claims A method of treating gastric cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody. The method of claim 1 , wherein the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6, and wherein the second domain that binds c-Met comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12. The method of claim 2, wherein the first domain that specifically binds EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain that specifically binds c-Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16. The method of claim 2 or 3, wherein the bispecific anti-EGFR/c-Met antibody is an IgGl isotype. The method of any one of claims 1-4, wherein the bispecific anti-EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20. The method of any one of claims 1-5, wherein the bispecific anti-EGFR/c-Met antibody comprises a biantennary glycan structure with a fucose content of about between 1 % to about 15%.
The method of any one of claims 1-6, wherein the bispecific anti-EGFR/c-Met antibody is administered intravenously or subcutaneously to the subject. The method of claim 7, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 3400 mg. The method of claim 8, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 350 mg, 700 mg, about 750 mg, about 800 mg, about 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, 2000 mg, 2100 mg, 2200 mg, 2240 mg, 2300 mg,
2400 mg, 2500 mg, 2600 mg, 2700 mg, 2800 mg, 2900 mg, 3000 mg, 3100 mg, 3200 mg, 3300 mg, 3360 mg, or 3400 mg. The method of claim 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1050 mg. The method of claim 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg. The method of claim 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1600 mg. The method of claim 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1750 mg. The method of claim 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg.
The method of claim 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg. The method of claim 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2400 mg. The method of claim 9, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg. The method of any one of claims 9-17, wherein the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally to the subject. The method of any one of claims 9-17, wherein the bispecific anti-EGFR/c-Met antibody is administered intravenously to the subject. The method of any one of claims 1-19, wherein the bispecific anti-EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks. The method of claim 20, wherein the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter. The method of claim 21, wherein the first dose of the bispecific anti-EGFR/c-Met antibody is administered over two days.
The method of any one of claims 1-22, wherein one or more cells of the gastric cancer express EGFR and/or cMet. The method of any one of claims 1-23, wherein the subject has received a prior treatment. The method of claim 24, wherein the prior treatment comprises a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a combination thereof. The method of claim 25, wherein the chemotherapy comprises a fluoropyrimidine -based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof. The method of claim 26, wherein the fluoropyrimidine is 5 -fluorouracil or capecitabine. The method of claim 26, wherein the platinum-based chemotherapy is cisplatin, oxaliplatin, carboplatin, or nedaplatin. The method of claim 25, wherein the targeted therapy comprises an anti-HER2 therapy or anti-VEGF/VEGFR therapy. The method of claim 29, wherein the anti-HER2 therapy comprises trastuzumab. The method of claim 30, wherein the anti-VEGF/VEGFR therapy comprises bevacizumab or ramucirumab.
The method of any one of claims 1-23, wherein the subject is treatment naive. The method of any one of claims 1-32, wherein the method further comprises administering at least one additional therapeutic to the subject. The method of claim 33, wherein the additional therapeutic comprises a glucocorticosteroid, antihistamine, antipyretic, H2-antagonist, antiemetic, opiate, or any combination thereof. The method of any one of claims 1-34, wherein the gastric cancer is an advanced or metastatic cancer. The method of any one of claims 1-35, wherein the subject is human. A method of treating esophageal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bispecific anti- epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody. The method of claim 37, wherein the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c- Met, wherein the first domain comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6, and wherein the second domain that binds c-Met comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
The method of claim 38, wherein the first domain that specifically binds EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain that specifically binds c- Met comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16. The method of claim 38 or 39, wherein the bispecific anti-EGFR/c-Met antibody is an IgGl isotype. The method of any one of claims 37-40, wherein the bispecific anti-EGFR/c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO: 20. The method of any one of claims 37-41, wherein the bispecific anti-EGFR/c-Met antibody comprises a biantennary glycan structure with a fucose content of about between 1% to about 15%. The method of any one of claims 37-42, wherein the bispecific anti-EGFR/c-Met antibody is administered intravenously or subcutaneously to the subject. The method of claim 43, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of between about 350 mg to about 3400 mg. The method of claim 44, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of about 350 mg, 700 mg, about 750 mg, about 800 mg, about 850
mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, 2000 mg, 2100 mg, 2200 mg, 2240 mg, 2300 mg, 2400 mg, 2500 mg, 2600 mg, 2700 mg, 2800 mg, 2900 mg, 3000 mg, 3100 mg, 3200 mg, 3300 mg, 3360 mg, or 3400 mg. The method of claim 45, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1050 mg. The method of claim 45, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1400 mg. The method of claim 45, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1600 mg. The method of claim 45, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 1750 mg. The method of claim 455, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2100 mg. The method of claim 455, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2240 mg. The method of claim 455, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 2400 mg. The method of claim 455, wherein the bispecific anti-EGFR/c-Met antibody is administered at a dose of 3360 mg. The method of any one of claims 37-53, wherein the bispecific anti-EGFR/c-Met antibody is administered subcutaneously or intradermally to the subject.
The method of any one of claims 46-53, wherein the bispecific anti-EGFR/c-Met antibody is administered intravenously to the subject. The method of any one of claims 37-55, wherein the bispecific anti-EGFR/c-Met antibody is administered twice a week, once a week, once in two weeks, once in three weeks or once in four weeks. The method of claim 56, wherein the bispecific anti-EGFR/c-Met antibody is administered once a week for four weeks and once in two weeks thereafter. The method of claim 57, wherein the first dose of the bispecific anti-EGFR/c-Met antibody is administered over two days. The method of any one of claims 37-58, wherein one or more cells of the esophageal cancer express EGFR and/or cMet. The method of any one of claims 37-59, wherein the subject has received a prior treatment. The method of claim 60, wherein the prior treatment comprises a chemotherapy, a targeted therapy, an immunotherapy, surgery, radiation therapy, chemoradiation therapy, or a combination thereof. The method of claim 61, wherein the chemotherapy comprises a fluoropyrimidine-based chemotherapy, a platinum-based chemotherapy, paclitaxel, irinotecan, or a combination thereof. The method of claim 62, wherein the fluoropyrimidine is 5 -fluorouracil or capecitabine. The method of claim 62, wherein the platinum-based chemotherapy is cisplatin, oxaliplatin, carboplatin, or nedaplatin.
The method of claim 61, wherein the targeted therapy comprises an anti-HER2 therapy or anti-VEGF/VEGFR therapy. The method of claim 65, wherein the anti-HER2 therapy comprises trastuzumab. The method of claim 65, wherein the anti-VEGF/VEGFR therapy comprises bevacizumab or ramucirumab. The method of any one of claims 37-59, wherein the subject is treatment naive. The method of any one of claims 37-68, wherein the method further comprises administering at least one additional therapeutic to the subject. The method of claim 69, wherein the additional therapeutic is a glucocorticosteroid, antihistamine, antipyretic, FE-antagonist, antiemetic, opiate, or any combination thereof. The method of any one of claims 37-70, wherein the esophageal cancer is an advanced or metastatic cancer. The method of any one of claims 37-71, wherein the subject is human.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263357218P | 2022-06-30 | 2022-06-30 | |
US63/357,218 | 2022-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024003837A1 true WO2024003837A1 (en) | 2024-01-04 |
Family
ID=87419298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/056787 WO2024003837A1 (en) | 2022-06-30 | 2023-06-29 | Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024003837A1 (en) |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
WO1998044001A1 (en) | 1997-03-27 | 1998-10-08 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
US20070287170A1 (en) | 2006-03-24 | 2007-12-13 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
WO2009018386A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
WO2009080252A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Bivalent, bispecific antibodies |
WO2009080254A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Bivalent, bispecific antibodies |
WO2009080251A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Bivalent, bispecific antibodies |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
US20100015133A1 (en) | 2005-03-31 | 2010-01-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for Producing Polypeptides by Regulating Polypeptide Association |
US20100028637A1 (en) | 2005-06-22 | 2010-02-04 | Sunjuet Deutschland Gmbh | Multi-Layer Film Comprising a Barrier Layer and an Antistatic Layer |
US20110123532A1 (en) | 2009-04-27 | 2011-05-26 | Oncomed Pharmaceuticals, Inc. | Method for Making Heteromultimeric Molecules |
WO2011131746A2 (en) | 2010-04-20 | 2011-10-27 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
US20120149876A1 (en) | 2010-11-05 | 2012-06-14 | Zymeworks Inc. | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20130195849A1 (en) | 2011-11-04 | 2013-08-01 | Zymeworks Inc. | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain |
EP2832748A1 (en) * | 2013-07-29 | 2015-02-04 | Samsung Electronics Co., Ltd | Anti-EGFR antibody and Anti-C-Met/Anti-EGFR bispecific antibodies comprising the same |
US9593164B2 (en) | 2012-11-21 | 2017-03-14 | Janssen Biotech, Inc. | Bispecific EGFR/c-Met antibodies |
US20220064307A1 (en) | 2020-08-26 | 2022-03-03 | Janssen Biotech, Inc. | Stable Formulations Comprising A Bispecific EGFR/C-Met Antibody |
WO2022043895A2 (en) * | 2020-08-25 | 2022-03-03 | Janssen Biotech, Inc. | Treatment of non-small lung cancer with egfr mutations |
US20220395573A1 (en) | 2021-04-21 | 2022-12-15 | Janssen Biotech, Inc. | High Concentration Bispecific Antibody Formulations |
-
2023
- 2023-06-29 WO PCT/IB2023/056787 patent/WO2024003837A1/en unknown
Patent Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
WO1998044001A1 (en) | 1997-03-27 | 1998-10-08 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
US20100015133A1 (en) | 2005-03-31 | 2010-01-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for Producing Polypeptides by Regulating Polypeptide Association |
US20100028637A1 (en) | 2005-06-22 | 2010-02-04 | Sunjuet Deutschland Gmbh | Multi-Layer Film Comprising a Barrier Layer and an Antistatic Layer |
US20070287170A1 (en) | 2006-03-24 | 2007-12-13 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
WO2009018386A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
WO2009080254A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Bivalent, bispecific antibodies |
WO2009080252A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Bivalent, bispecific antibodies |
WO2009080251A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Bivalent, bispecific antibodies |
US20110123532A1 (en) | 2009-04-27 | 2011-05-26 | Oncomed Pharmaceuticals, Inc. | Method for Making Heteromultimeric Molecules |
WO2011131746A2 (en) | 2010-04-20 | 2011-10-27 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
US20120149876A1 (en) | 2010-11-05 | 2012-06-14 | Zymeworks Inc. | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain |
US20130195849A1 (en) | 2011-11-04 | 2013-08-01 | Zymeworks Inc. | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain |
US9593164B2 (en) | 2012-11-21 | 2017-03-14 | Janssen Biotech, Inc. | Bispecific EGFR/c-Met antibodies |
EP3808767A1 (en) * | 2012-11-21 | 2021-04-21 | Janssen Biotech, Inc. | Bispecific egfr/c-met antibodies |
EP2832748A1 (en) * | 2013-07-29 | 2015-02-04 | Samsung Electronics Co., Ltd | Anti-EGFR antibody and Anti-C-Met/Anti-EGFR bispecific antibodies comprising the same |
WO2022043895A2 (en) * | 2020-08-25 | 2022-03-03 | Janssen Biotech, Inc. | Treatment of non-small lung cancer with egfr mutations |
US20220064307A1 (en) | 2020-08-26 | 2022-03-03 | Janssen Biotech, Inc. | Stable Formulations Comprising A Bispecific EGFR/C-Met Antibody |
US20220395573A1 (en) | 2021-04-21 | 2022-12-15 | Janssen Biotech, Inc. | High Concentration Bispecific Antibody Formulations |
Non-Patent Citations (22)
Title |
---|
"GenBank", Database accession no. NP_001120972 |
"Remington: The Science and Practice of Pharmacy", 2006, LIPINCOTT WILLIAMS AND WILKINS, article "Pharmaceutical Manufacturing", pages: 691 - 1092 |
ANONYMOUS: "NCT04945733 A study of Amivantamab in participants with previously treated advanced or metastatic gastric or esophageal cancer", 16 June 2022 (2022-06-16), pages 1 - 6, XP093079849, Retrieved from the Internet <URL:https://classic.clinicaltrials.gov/ct2/history/NCT04945733?A=1&B=14&C=merged#StudyPageTop> [retrieved on 20230907] * |
ANONYMOUS: "NCT05117931 A study of Amivantamab in people with esophagogastric cancer", 1 November 2021 (2021-11-01), pages 1 - 5, XP093079838, Retrieved from the Internet <URL:https://classic.clinicaltrials.gov/ct2/history/NCT05117931?V_1=View#StudyPageTop> [retrieved on 20230907] * |
CHOTHIA, J MOL BIOL, vol. 196, 1987, pages 901 - 17 |
FERRARA ET AL., BIOTECHNOL BIOENG, vol. 93, 2006, pages 851 - 861 |
FERRARA ET AL., J BIOL CHEM, vol. 281, 2006, pages 5032 - 5036 |
HIRSCH FR ET AL., J CLIN ONCOL, vol. 21, 2003, pages 3798 - 3807 |
HONEGGERPLUCKTHUN, J MOL BIOL, vol. 309, 2001, pages 657 - 70 |
JOHN T ET AL., ONCOGENE, vol. 28, 2009, pages S14 - S23 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH |
KONNO ET AL., CYTOTECHNOLOGY, vol. 64, 2012, pages 249 - 65 |
LEFRANC ET AL., DEV COMP IMMUNOL, vol. 27, 2003, pages 55 - 77 |
MARTINTHORNTON, J BMOL BIOL, vol. 263, 1996, pages 800 - 15 |
MORI ET AL., BIOTECHNOL BIOENG, vol. 88, 2004, pages 901 - 908 |
NEIJSSEN JOOST ET AL: "Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 296, 8 April 2021 (2021-04-08), US, pages 100641, XP093079840, ISSN: 0021-9258, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113745/pdf/main.pdf> DOI: 10.1016/j.jbc.2021.100641 * |
OLIVIER ET AL., MABS, vol. 2, 2010, pages 4 |
SHIELDS ET AL., J BIOL CHEM, vol. 277, 2002, pages 26733 - 26740 |
SHINKAWA ET AL., J BIOL CHEM, vol. 278, 2003, pages 3466 - 3473 |
ULLRICH ET AL., NATURE, vol. 309, 1984, pages 418 - 425 |
WU ET AL., J EXP MED, vol. 132, 1970, pages 211 - 50 |
XHOU ET AL., BIOTECHNOL BIOENG, vol. 99, 2008, pages 652 - 65 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11879013B2 (en) | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors | |
KR20220133243A (en) | Method of treating cancer using anti-TIGIT antagonist antibody | |
JP7299842B2 (en) | Anti-FGFR2 Antibodies in Combination with Chemotherapeutic Agents in Cancer Treatment | |
US20230131598A1 (en) | Combination treatment for cancer | |
US11850248B2 (en) | Therapies with 3rd generation EGFR tyrosine kinase inhibitors | |
KR20220140794A (en) | Treatment of patients with c-MET exon 14 skipping mutations | |
JP2022543780A (en) | Combination cancer treatment of anti-galectin 9 antibody and chemotherapeutic agent | |
WO2022109302A1 (en) | Anti-galectin-9 antibodies and therapeutic uses thereof | |
WO2024003837A1 (en) | Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer | |
US20240067736A1 (en) | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | |
US20240109969A1 (en) | Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodies | |
US20240180917A1 (en) | Therapies with 3rd generation egfr tyrosine kinase inhibitors | |
US20230183360A1 (en) | Use of Amivantamab to Treat Colorectal Cancer | |
US20220372581A1 (en) | Methods for Identifying Cancer Patients for Combination Treatment | |
US20230140694A1 (en) | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies | |
KR20240028452A (en) | Methods and compositions for treating cancer | |
CA3140360A1 (en) | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors | |
WO2023010095A1 (en) | Methods and compositions for treating cancer | |
TW202342057A (en) | Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies | |
CN117940452A (en) | Methods and compositions for treating cancer | |
CN117202897A (en) | Combination therapy using RAF inhibitors and PD-1 axis inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23744239 Country of ref document: EP Kind code of ref document: A1 |